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Abstract
A series of amphipathic peptides rich in a , a-disubstituted amino acids 
(aaA A ’s) was synthesized and studied for antimicrobial activity and helix 
preferences in various solvent systems. In addition, a constrained lactam dipeptide 
amino acid was synthesized and incorporated into a peptide to examine p-sheet dimer 
formation.
Several short, amphipathic, 310- and a-helical peptides containing 80% 
aotAA’s were synthesized using various combinations of 1-aminocyclohexane-l- 
carboxylic acid, a-aminoisobutyric acid, and 4-aminopiperidine-4-carboxylic acid. 
The peptides showed direct antimicrobial activity against E. coli and S. aureus. In 
addition, several of the peptides showed in vivo and in vitro activity against Brucella 
abortus and Mycobacterium chelonei. Studies were done with a strain of B. abortus 
expressing a green fluorescent protein to show the peptides selectively destroyed 
infected macrophages.
The series of amphipathic 3i0- and a-helical peptides were also studied, using 
circular dichroism spectroscopy, for their helix preference in organic and aqueous- 
organic solvent systems. The a-helical peptides showed the expected spectra in all 
solvents used. One designed 310-helical peptide exhibited a transition from a 3i0-helix 
to an a-helix as the water content was increased. The other designed 3i0-helical
Xlll
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peptide exhibited a spectrum indicative of an a-helix in all solvents tested, 
presumably due to steric interactions o f the amino acid side-chains.
A constrained lactam dipeptide amino acid, 3-(R)-Ar'-[(9H-fluoren-9- 
ylmethoxy)carbonyI]-amino-1 -[ 1 -(S)-methylethylethanoic acid]-2-piperidinone, was 
synthesized from D-glutamic acid and incorporated into a peptide. The starting 
material was esterified with allyl alcohol and the a-nitrogen was doubly protected 
with Boc protecting groups. Selective DIBAL reduction of the side-chain ester 
yielded the semi-aldehyde. Reductive amination with valine followed by removal of 
the remaining allyl ester and intramolecular amide bond formation yielded the fully 
protected constrained lactam dipeptide amino acid. Treatment with TFA and 
introduction of the Fmoc protecting group resulted in the amino acid ready for peptide 
coupling. A peptide using the constrained amino acid was synthesized and studied for 
[3-sheet dimer formation.
xiv
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Chapter 1 
Introduction
1.1 Introduction
The basic component of ail proteins and peptides is the amino acid. There are 
approximately twenty encoded and hundreds of post-translationally modified amino 
acids in nature that have the general structure shown in Figure 1.1
OI
H2N CH— C  OHI
R
Figure 1.1. General structure of an amino acid.
As can be seen in Figure 1.1, the proteinogenic amino acids, with the exception 
of glycine, exist as enantiomers. In nature, the L-amino acid is the most common. The 
structures of the side chains of the twenty encoded amino acids are the distinguishing 
feature. The carbon atom bonded to the carbonyl carbon depicted in Figure 1.1 is 
designated as a  and the atoms of the side chains are commonly designated as p, y, 6, e, £, 
in order away from the a  carbon.
Amino acids that can be incorporated into proteins and peptides are not limited to 
the twenty encoded ones. Synthetic amino acids are routinely included in many protein 
and peptide sequences. Side chains that do not occur in biological systems distinguish 
synthetic amino acids from their natural counterparts. As a result, many synthetic amino
1
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acids are incorporated into peptides to study their effects on the peptide’s secondary 
structure.
1.2 Secondary Structures in Peptides
Amino acids can be chemically bonded to each other to form peptides and proteins. 
A peptide is generally considered a short chain of residues with a defined sequence. 
There is no maximum number of residues but if the physical properties of the chain are 
those expected from the sum of the residues and no fixed three-dimensional 
conformation exists, the term peptide is appropriate. The term protein is usually used for 
those polypeptides that occur in nature and have definite three-dimensional structure
under physiological conditions.1' 1 This volume of work will focus on peptides.
The backbone of a peptide chain consists of a repeated sequence of three atoms of
each residue in the chain -  the amide N, the C“ and the carbonyl C. These atoms are
represented as Ns, C “, and C ,, respectively, where i is the number of the residue starting
from the amino end of the chain.
Peptides can adopt defined 3-D structures that are primarily stabilized by hydrogen
1 l-l  4bonds and secondarily by hydrophobic, electrostatic and steric interactions.
Helices and turns depend on intramolecular hydrogen bonds in the peptide chain for
structural stability. {3-sheets form as a result of either inter or intramolecular hydrogen
bonds between peptide segments. Hydrophobic interactions further stabilize the (3-sheet.
Secondary structures that are not included above are classified as random coil. The
random coil has no regular, repeating structure in significant stretches of the peptide 
1 4chain. ' The (3-sheet results from two or more ^-strands forming interchain hydrogen
2
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1 1-1 4bonds. Two types of [3-sheet are known: anti-parallel and parallel. ' The N—>C
sequence of the participating strands occur in the same direction in  the parallel [3-sheet. 
In the anti-parallel [3-sheet, the N—»C sequence is opposite in the participating strands. 
The (3-strands comprising the (3-sheet are almost fully extended with hydrogen bonds 
occurring between every other carbonyl oxygen and amide proton in the opposing 
strands. The hydrogen bonding patterns of the two types are shown in Figure 1.2.
A — ^/ = o ^  y=o y= o — h —n
H—N 'H -N  H—N y=0
J  J  J  <0 = \  ^ 0 = (  0 = (  N -H
N - H ''  N- H  N -H --------0 = (
c  < c  >/ = 0 ^  y=o ^=0 ------- H—N
H -N  ' 'H -N  H -N  V = 0
J  J  J  <0 = \  , - - 0 = r (  0 = ^  N -H
N - H ' '  n - H  N -H --------0 = ^
/= o ^  ^=o S= ° — H—N
H -N  ''H —N H—N ) = 0y  y  y
Parallel Antiparallel
Figure 1.2. Hydrogen bonding patterns of the beta sheet structures.
3
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Turns are types of secondary structures that help promote a change in direction of a 
1 1 1 3peptide chain. ' Incorporation of a turn allows helices and (3-sheets to fold back on
themselves. Turns are distinguished by the number of residues they contain. (3-Tums
have four residues and a hydrogen bond between the carbonyl of the /th residue and the
amide proton of the t* + 3 residue. y-Tums contain three residues and a hydrogen bond
between the /*h and /*" + 2 residues. The types of turns are defined by the conformations
of the /*** + 1 residue in the y-tum and the i* + 1 and /* + 2 torsional angles in the (3- 
1.3turns.
The most common secondary structure is the helix. Helices are stabilized by
hydrogen bonds that are almost parallel to the helix axis. The hydrogen bond acceptors
are the carbonyl oxygens while the hydrogen bond donors are the amide hydrogens. Side
chain interactions, such as salt bridges, hydrophobic interactions and steric constraints,
1 1-1 4may further stabilize the helix. ' The right-handed helix, promoted by L-ammo
acids, is the most common form of helix found in nature. The left-handed helix is
promoted by D-amino acids and is far less common in nature. The two most common
helices are the a-helix and the 3i0-helix. The a-helix comprises approximately 90% of
all helices found in nature. In this helix type, the amide proton of the /th residue is the
hydrogen bond donor while the carbonyl oxygen of the i* + 4 residue is the hydrogen
bond acceptor. There are 3.6 residues per turn and a pitch of 1.5A per residue. The a-
helix is also known as a 3.6I3-helix with 3.6 being the number of residues per turn and 13
1 l - l  4being the number of atoms between the hydrogen bond donor and acceptor.
4
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The 3,0-helix comprises approximately 10% of all helical structures found in 
nature.1'5 ,1-6 The amide proton of the /th residue acts as the hydrogen bond donor while
the carbonyl oxygen of the /* + 3 residue acts as the hydrogen bond acceptor. This 
hydrogen bonding pattern results in a 10-membered ring. As a result, the 3)0- helix is
more compact and longer than the a-helix.1'3, 1,6 Figure 1.3 shows the hydrogen
bonding patterns of the a-helix and 3i0-helix.
Determining secondary structure a priori from the amino acid sequence (known as 
primary structure) is the ultimate goal of peptide and protein chemistry. Ideally, if one 
wishes to design a peptide or protein with a particular secondary structure, we would 
only need to include those amino acids known to promote the desired structure. 
Unfortunately, this task is not so simple as many factors (i.e., hydrogen bonding, 
electrostatic and hydrophobic interactions) affect secondary structure. However, one can 
gain much information by studying the conformational restrictions placed on the peptide 
backbone.
Figure 1.4 shows the conventions used in describing peptide conformation. 
Rotations about bonds are defined as torsion or dihedral angles that lie from -180° to 
+180°. Rotation about the N-Ca bond is denoted by <t>; rotation about the C“-C' bond by 
i|/; and rotation about C'-N by co. Table 1.1 shows the ideal <(> and y  angles for the right- 
handed a-helix, antiparallel (3-sheet, parallel P-sheet and 310-helix. Table 1.2 shows the 
dihedral angles for the residues in the y-tum and several representative P-tums. Often, 
these values vary slightly in natural proteins, depending on the environment. These 
variations in the dihedral angles maximize hydrogen bonding, hydrophobic/electrostatic
5
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> °
N-H
H-N
N-H
H-N
N-H
H-N
N-H
H-N
N-H
0= < > 
H-N + 
H H
H -N
N -H
H -N
N -H
H -N
N -H
H -N
H-N
N-H
H“ N + 
H H
a-Helix 310-Helix
Figure 1.3. Hydrogen bonding patterns in helices.
6
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Table 1.1
Dihedral angles for common secondary structures.1' 1
Bond Angle (deg)
0 V 0)
Right-handed a-helix -57 -47 180
Antiparallel P-sheet -139 +135 -178
Parallel P-sheet -119 +113 180
3I0-helix -49 -26 180
Table 1.2
Common dihedral angles of selected y and P turns.1' 1
Dihedral Angles of Central Residues (deg)a
Bend type 0i+l ¥«+i 01+2 Vi+2
Classical y 70 to 85 -60 to -7 0 — —
Type T P 60 30 90 0
Type IT p 60 -120 -80 0
a The central residue of a y turn is numbered i + 2; the two central residues of a p turn are 
/ + 2 and / + 3.
7
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Figure 1.4. Torsion angles of the peptide bond, 
interactions within the protein and interactions between the protein and the aqueous 
solvent. The values of <j> and y  available to amino acid residues in a particular secondary 
structure are indicated on a two-dimensional map of the $-\\i plane known as a 
Ramachandran plot.1' 1
1.3 Antimicrobial Peptides
Antimicrobial peptides have been isolated from many different organisms including
insects, mammals, amphibians, bacteria and plants.1"7 Antimicrobial peptides contain
many structural similarities. While most are unstructured in aqueous media, many adopt
an amphipathic a-helix in membrane environments.1"8' 1' 10 Amphipathic alpha helices
possess a hydrophobic or non-polar face and a hydrophilic or polar face. Peptides that 
contain an amphipathic a-helix tend to self-associate allowing the hydrophobic regions 
to interact while exposing polar regions to the polar media. Figure 1.5 shows a Schiffer-
8
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Edmunson helical wheel diagram of the a-helix.1' 11 The wheel is shown looking down
the helix axis from the C-terminus to the N-terminus. P represents the polar residues 
while N represents the non-polar residues.
Antimicrobial peptides are usually smaller than 40 residues long and contain 
virtually equal numbers of polar and non-polar residues. As a result, the polar face is
usually less than 180°.1-10 Cationic residues occur more often than anionic residues
1 12resulting in an overall positive charge at physiological pH. ‘ Three classes of
antimicrobial peptides have been extensively studied: melittin, magainins, and
1.10,1.13cecropms.
Isolated from the venom of the honeybee, Apis mellifera, melittin is a twenty-six
1 13residue antimicrobial peptide. ' Like most antimicrobial peptides, melittin assumes no
observable secondary structure in aqueous media at low concentrations but adopts an
amphipathic a-helix at high concentrations or membrane environments.1' 10 Melittin
exhibits broad spectrum antimicrobial activity with minimum inhibitory concentrations
1 12(MICs) in the pM range. ' Melittin’s highly hemolytic nature limits its therapeutic
1.10use.
Cecropin A is a 37 residue antimicrobial peptide isolated form the North 
American silk moth, Hyalophora cecropia. 1' 10 Cecropin A consists of two helical
regions. Helix 1 adopts an amphipathic a-helix structure while helix 2 remains largely 
hydrophobic. This peptide exhibits high antimicrobial activity against representative
9
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Figure 1.5. Helical wheel diagram of an amphipathic a-helix.
Gram-negative and Gram-positive bacteria while showing no hemolysis at these
1.10concentrations.
Magainin 2 is a twenty-three residue antimicrobial peptide isolated from the skin of
the frog Xenopus laevis. It too adopts an amphipathic a-helix in membrane
environments. Magainin 2 possesses broad spectrum antimicrobial activities and is non-
1 14hemolytic at concentrations that are effective for antimicrobial activity.
1.4 Mechanisms of Action of Antimicrobial Peptides
The target of antimicrobial peptides is the phospholipid bilayer of bacteria. The 
exact mechanism of action is not known. It is thought that the initial interaction between
10
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the peptide and bacteria is an electrostatic interaction.1' 15 Two mechanisms o f action on
membranes have been proposed: the raft or carpet model and the barrel-stave or pore
model.1' 15’ 116 Figure 1.6 shows each. In the raft model, the amphipathic a-helical
peptides first bind onto the surface of the target membrane. The target membrane can 
only be disrupted after a threshold peptide concentration has been reached. The peptide 
does not insert into the hydrophobic core of the membrane but binds to the phospholipid 
headgroups. The process of cell disruption via this method consists of four steps: (a) 
preferential binding of positively charged peptide monomers to the negatively charged 
phospholipid headgroups; (b) orientation of amphipathic a-helical monomers on the 
surface of the membrane so that the positively charged monomers can interact with the 
negatively charged phospholipid headgroups or water molecules; (c) partial insertion of 
the peptide into the membrane so that the hydrophobic residues interact with the 
hydrophobic core of the membrane; and (d) destroying the membrane by disrupting the
bilayer curvature leading to micellization.1' 16 In the pore model, transmembrane
amphipathic a-helices form bundles, in which their hydrophobic surfaces interact with 
the lipid core of the membrane. In this orientation, the hydrophilic surfaces point 
inward, producing a pore. In this model, the peptide binding to the membrane is driven 
by hydrophobic interactions. As a result, the peptide can bind to both zwitterionic and 
charged phospholipid membranes. Membrane destruction via this mechanism involves 
four steps: (a) binding of the helical peptide monomers to the membrane; (b)
aggregation of the membrane bound monomers; (c) insertion of at least two assembled 
monomers into the membrane to begin the pore formation; and (d) recruitment of
11
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additional monomers to increase the pore size leading to membrane disruption. Initial
assembly of the monomers must occur before insertion into the cell membrane as it is
energetically unfavorable for a single amphipathic a-helix to span the membrane as a 
1.16monomer.
1.5 Protein Structure and Amyloid Disorders
Many diseases are characterized by the presence of protein aggregates that form as
fibrillar structures known amyloid plaques. These plaques are rich in beta sheet
structures and insoluble under physiological conditions. Their presence may result from
genetic anomalies, accumulation of over the lifetime of the individual or exposure to
exogenous prion proteins. Among these diseases are Alzheimer’s disease (AD), type II
diabetes. Creutzfeldt-Jacob disease (CJD), Parkinson’s and Huntington’s diseases,
kuru and bovine spongiform encephalopathy (mad cow disease). There has been much
speculation about what role the fibrillar structures play in the pathology of these diseases.
Two theories have evolved to explain the presence of the structures. One posits that the
fibrillar structures are the causative agent of the diseases. The other suggests that the
1 17-1 20fibrils are a result linked to the disease but are not the causative agent.
Many believe that the fibrils are the result of a normal protein misfolding to an
abnormal isoform. This abnormal isoform is rich in beta sheet structures resulting in the
formation of insoluble fibrils and protofibrils. Several proteins can misfold, each
resulting in a different disease. For example, the protein associated with AD is the
amyloid p -peptide (AP) while the protein for CJD and other encepholapathies is the 
1 17-1 19prion protein (PrP). ' Since the amyloid plaques associated with all of these
12
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Figure 1.6. Mechanisms of action of antimicrobial peptides.1' 16
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diseases are comprised largely of beta sheets, it would be beneficial to study the factors
that form and stabilize this secondary structure. If these factors can be elucidated, it may
be possible to inhibit or even reverse the formation of the fibrillar structures linked to
many of these degenerative diseases.
The beta sheet is the second most common secondary structure found in peptides
and proteins, but relatively little is known about the factors that stabilize this structure.
I 21Very few beta sheet models lend themselves to detailed study. ' Much of the recent
work done to study beta sheets has centered around synthesizing unnatural amino acids
1 21-1 ^5to act as a turn thus nucleating beta sheet formation. These amino acids are
successful in promoting beta sheets because they effectively tie the strands together, thus 
overcoming entropy. As a result, the beta sheet formed is an intramolecular structure.
Kelly reports that while the entropy barrier is significant, the resulting hydrogen bonds
I ’’2alone are insufficient to maintain the beta sheet structure. It is believed that
1 22hydrophobic interactions are also necessary to stabilize the structure. ' To date, there
are no known peptides that have been synthesized to reversibly form an intermolecular 
beta sheet.
1.6 Peptide Synthesis
The synthesis of helical peptides requires amino acids that promote this secondary 
structure. The many studies that have investigated the helix-promoting capacity of the 
natural amino acids have focused on the frequency of these amino acids in helical 
regions of proteins and peptides or on the effects of substituting a proteinogenic amino
14
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1 26-1 ?8acid in the helical region of a peptide or protein. ' ~ These studies found that
alanine, leucine, and lysine promote helical structures while proline and glycine break
. . .  . _  „  1.26, 1.27helical structures.
As peptide length decreases, the proteinogenic amino acids that promote helicity do
so to the extent required. Other non-natural amino acids were then investigated for their
helix promoting ability. The first discovered was a-aminoisobutyric acid (Aib). Its
presence in the peptide, alamethicin, prompted investigators to postulate that Aib was a
strong helix promoter. Alamethicin was found to be more helical than was predicted
1 29based on the natural amino acids.
It has been shown that residues that are disubstituted at the a-carbon like Aib, where 
the R groups are not very large, promote helical structures. The presence of the 
additional R group limits the possible conformations of the residue in the peptide. As a 
result, the rotation of the <j>, y  angles is restricted. In the case of Aib, the angles are 
limited to <j> = -60760° and y  = -30730° for the left-handed and right-handed 310-helices.
For a-helices, 0 = -55755° and y  = -45745° for the left-handed and right-handed
. .. 1.30, 1.31helices.
Many other a,a-disubstituted amino acids (aaA A ’s) have been synthesized and
1 31-1 40their effects on secondary structure studied. ' A series of aaA A ’s have been
studied in which the R groups on the a-carbon are identical and are not in a ring system.
Examples are diethylglycine, di-n-propylglycine, di-n-butylglycine, diphenylglycine and
1 31dibenzylglycine. These amino acids, unlike Aib, promote extended conformations.
15
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While larger, acyclic R groups promote extended conformations, cyclic, aliphatic 
aaA A ’s can promote helical structures. 1-Aminocyclobutane carboxylic acid, 1- 
aminocyclopentane carboxylic acid, 1-aminocyclohexane carboxylic acid and 1-amino 
cycloheptane carboxylic acid promote helical formation. 1-Aminocyclooctane 
carboxylic acid forms a 3,0-helix or (3-bend structure while 1-aminocyclopropane
131 1 33carboxylic acid forms a distorted 3,0-helix. ‘ ’
In order to study amphipathic peptides containing aaA A ’s, several polar aaA A ’s 
1 37-1 40have been synthesized. ' These polar aaA A ’s are believed to promote the same
secondary structures as their non-polar counterparts. Orthogonal protection of the side 
chain with respect to the a-amine or carboxylic acid is necessary for the incorporation of 
the amino acid into a peptide. As a result, incorporation of polar aaA A ’s allows one to 
synthesize water-soluble peptides that contain high percentage of aaA A ’s. In turn, these 
peptides can be designed to be amphipathic and used for biological studies.
1.7 Incorporation of a,a-Disubstituted Amino Acids Into Peptides
1 32Incorporating aaA A ’s into a peptide has proven difficult. ' The additional R
group on the a-carbon substantially increases steric bulk, making oaAA couplings 
1 41difficult. ' Traditional coupling reagents such as carbodiimides (i.e. dicyclohexyl
carbodiimide or diisopropyl carbodiimide) or 1-hydroxybenzotriazole (HoBT) rarely
1 42improve the yields of aaA A  couplings. ‘ In addition, (benzotriazolyloxy)-tns-
(dimethylamino) phosphonium hexafluorophosphate or O-benzotriazolyl-M N, N ' N -
1 41tetramethyluronium hexafluorophosphate have not improved coupling yields.
16
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As a result of the limited success in aaA A  couplings, new methods have been
pursued to improve coupling yields. Acid chlorides, oxazolones, N-carboxyanhydrides
1 41(NCA’s) and 2-(dimethylamino)-3,3/-dimethylozirine are a few of the methods used. ‘ ' 
1 43 1 44' * Each of these methods has improved a a A A  coupling yields but each suffers
disadvantages. Acid chloride use is limited because of harsh conditions for its formation
1 43and its tendency to form oxazolones. ' NCA’s and oxazolones suffer from side
product formation accompanying the couplings. Hydrolysis following azirine coupling
1 41 i 44
severely limits its usefulness in peptide synthesis. * ’
Some degree of success has been recently achieved in improving aaA A  coupling 
yields. The most noted are the use of acid fluorides or other coupling reagents such as 7- 
azabenzotriazole- l-yloxytris(pyrrolindino)phosphonium hexafluorophosphate (PyAOP) 
or N-[[dimethyl amino-)-1H-1,2,3-triazole[4,5-b]pyrindin-1 -yl]methylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HATU).1'41’ 145 148 The acid
fluoride method developed by Carpino can give high aaA A  couplings under mild
conditions and is useful in either solution phase synthesis or solid phase peptide 
141 1 45 1 46synthesis (S P P S ).  The preformed acid fluorides are reacted with the free
amine of another amino acid in the presence of base (e.g., N, N-diisopropylethylamine, 
DEEA). The acid fluoride can be prepared by treating the amino protected amino acid
with cyanuric fluoride and pyridine or in situ with tetramethylfluorformamidinium
  149-151hexafluorophosphate (TFFH).
17
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1.8 Effects of a,a-Disubstituted Amino Acids on Secondary Structure
As mentioned previously, the three major secondary structures are the a-helix, 3I0- 
helix and beta sheet. aaA A ’s have been shown to promote each of these structures. The 
beta sheet is usually promoted by aaA A ’s that have large, bulky a-substitutents.1 '31
Cyclic aaA A ’s, with 8-membered or smaller rings, and aaA A ’s with a methyl group as 
one of the a-substitutents promote 3,0-helices or a-helices. The preference for which 
helix type depends on the peptide design, the environment, location and number of 
aaA A ’s.
Many groups have studied the equilibrium between 3I0- and a-helices because the 
3I0-helix is thought to be a folding intermediate to the a-helix and is thought to play a 
role in receptor binding.1'52 155 Several studies have been done which characterize
both helix types in short peptides containing a a A A ’s .1'53 1 55 Until recently, the use of
hydrophobic amino acids has prevented studies in aqueous media.
Many factors have been postulated for the prediction of the type of helix formed in
short peptides rich in aaA A ’s. The length of the peptide, percentage of aaA A ’s,
location of monosubstituted amino acids, and the solvent effects are among the major
1 44 1 5"M 59factors believed to be involved in the 3io/a-helix equilibrium. ' Peptide
length is believed to play an important role in helix preference. Karle reported that Aib
rich peptides with five residues or less form 3i0-helices, while peptides with ten or more
1 53residues form a-helices. Aib rich peptides between five and ten residues do not
18
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appear to have a helix preference but many still believe peptide length is an important
131 1 53factor in preferential helix formation.
The percentage of aaA A ’s incorporated in a peptide is also believed to have an
influence on helix formation. This factor is significant for medium length peptides (7-10
residues) which can form either a 310-helix or an a-helix. Peptides with at least seven
residues and 50% or more aaA A ’s form a 3i0-helix while those containing less than
1 5350% aaA A  content favor an a-helix.
It has been suggested that the location of monosubstituted amino acids in aaA A  rich
1 44peptides is more important on the helix preference than the percentage of aaA A ’s.
This factor was studied using peptides containing 75% Aib residues. Incorporating two
monosubstituted amino acids consecutively in the peptide sequence resulted in 310-helix 
1 44formation.
Helix preference may also be influenced by the media surrounding the peptide. The 
polarity of organic solvents used in crystallization and NMR studies has influenced helix
preference.1'55’ 157 159 One experiment performed on an Aib rich peptide showed a-
helix formation in dimethyl sulfoxide (DMSO) while the helix type shifted to a 310-helix
when chloroform was used.1'57 Another experiment with Aib rich peptides showed an
a-helix is preferred when water is present and a 3i0-helix is preferred under anhydrous 
158 1 59conditions. ’ In crystallization experiments, an a-helix and 3i0-helix was
obtained using methanol and methanol/ethyl ether solvent systems respectively.1'55
19
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Based on these studies, it appears that polar solvents favor an a-helix while less polar 
solvents favor a 310-helix.
Theoretical calculations have been performed to further probe the effects of solvent 
polarity on helix preference. The a-helix appears to be favored thermodynamically 
while the 3I0-helix is favored entropically. The theoretical studies confirm what has been 
observed experimentally. Specifically, the 3i0-helix is favored in short, Aib-rich peptides 
while the a-helix is favored in longer peptides. In addition, the two helix types have the 
same energy in peptides with a length of 7.5 residues. This agrees with the observed data 
presented by Karle and others who report an equal helix preference for peptides between
seven and ten residues.1’53, 1-56 For peptides of this length, the solvent significantly
affects the 310-/a-helix equilibrium.
To study the solvent effects on 3I0-/a-helix equilibrium, four media, vacuum, 
methylene chloride, acetonitrile, and water were examined using a poly-Aib 10-mer 
peptide. In lower polarity environments, the 3i0-helix is slightly more stable. As the 
polarity of the media increases, the a-helix becomes more stable. The correlation of a- 
helix stability to increasing solvent polarity can be attributed to peptide-solvent 
interactions. In a ten-residue peptide, the a-helix forms six intramolecular hydrogen 
bonds. This leaves three N-terminal amide hydrogens and four C-terminal carbonyl 
oxygens without internal hydrogen bonding partners. In a ten residue 3i0-helix, seven 
intramolecular hydrogen bonds are possible. This leaves two N-terminal amide protons 
and three C-terminal carbonyl oxygens without hydrogen bonding partners (Figure 1.3). 
As a result of the additional exposed carbonyl and amide protons, the a-helix has more
20
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favorable interactions with the solvent thereby increasing stability. In non-polar 
environments, the 3 i0-helix gains stability form the extra intramolecular hydrogen bonds
present as compared to the a-helix.1'56
1.9 Characterization of Peptide Secondary Structure
There are several techniques, such as X-ray crystallography and NMR for the
characterization of secondary structure. However, neither is as convenient and reliable
as circular dichroism (CD). In ultraviolet-visible light spectroscopy, organic molecules
absorb radiation via the promotion of electrons to higher energy molecular orbitals.
Circular dichroism takes advantage of this phenomenon and carries it one step further.
Optically active (i.e., chiral) organic molecules rotate plane-polarized light. Plane
polarized light can be resolved into its two circularly polarized components: left
circularly polarized light (LCP) and right circularly polarized light (RCP). The electric
vector of LCP rotates counterclockwise about the axis perpendicular to the direction of
travel of the light beam while the electric vector of RCP rotates clockwise. A chiral
molecule produces a circular dichroism spectrum because its absorption of LCP is not
equal to its absorption of RCP. After passing through a chiral medium, the electric
vectors describe an ellipse whose major axis lies along a new angle of rotation. The
measured eccentricity of the ellipse represents the unequal absorption of LCP and RCP
referred to as circular dichroism. Analogous to Beer’s law, the experimentally measured
ellipticity is equal to 6cd where 6 is the molar value in radians, c is the molar
concentration and d is the cell path length in centimeters. A circular dichroism spectrum
1 60-1 62plots the molar ellipticity versus wavelength.
21
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CD is useful in determining the secondary structure of peptides because in the 
absence of aromatic amino acid residues, only the peptide backbone contributes 
significantly in the far UV region as the spectrum reflects the spatial arrangement of 
chiral units in the peptide chain. The presence of aromatic amino acids induces a
positive CD signal, causing significant errors in ellipticity values.1'63 1-65 The three
main classes of secondary structure, the alpha helix, 310-helix, and beta sheet as well as 
the random coil, can be distinguished by their CD spectra. Figure 1.7 shows the typical
CD spectrum for each of these secondary structures.1'61
Helical peptides, the a-helix and 3 i0-helix, exhibit two minima near 208 nm 
(k— and 222 nm (n—»7t*|) and a positive band near 195 nm (tc—>7C*_L). The 310-helix 
and the a-helix spectra are very similar but can be easily distinguished. The ratio, R, of 
the intensity of the 222 nm band divided by the intensity of the minimum near 208 nm is 
used to differentiate between the 3i0-helix and the a-helix. The ratio is approximately 1 
for the a-helix, while the ratio is 0.4 or less for the 310-helix. Also, the positive band 
near 195 nm is much weaker for the 3i0-helix as compared to the a-helix. Few CD 
spectra o f 310-helices have been reported. To date, experimental spectra reported agree
well with the theoretically calculated 3i0-helix CD spectra.1'60' 166~1-69
The (3-sheet and random coil, are easily distinguished from each other. The |3-sheet 
exhibits a negative band near 217 nm representing an n—>it’ transition and a positive 
band near 195 nm representing a jc—>tc* transition. The random coil exhibits a strong 
negative band near 197 nm (jc-mc*) and a small positive band at 217 nm (n—mc’).1'60
22
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Peptide conformation is highly sensitive to solution variables; a peptide may be 
insoluble in one condition, but well behaved under others. In characterizing the 
secondary structure of peptides by CD, the effect of pH, ionic strength of the buffer and 
peptide concentration should be examined. As a general rule, aggregation increases with 
peptide concentration, ionic strength or pH. Concentration dependence reveals whether 
the peptide is monomeric or self-associating. For example, a shift from random coil to 
beta sheet as the peptide concentration increases indicates an association equilibrium. 
Self-association may be obtained by changing pH (usually increasing) to titrate the 
amino groups present in the peptide sequence or by changing the ionic strength of the 
buffer to optimize charge screening. Variations in these parameters are examined 
systematically in an effort to determine the number and type of species present in the
solution. Stable equilibrium between only two states are identified by the presence of an
. ..  . . 1.60 . 1.61 isodichroic point.
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Chapter 2 
a , a-Disubstituted Amino Add Rich Peptides Active Against Intracellular 
Pathogens
2.1 Introduction
While antibiotics have saved countless lives by fighting bacterial infections, bacteria
o 1-2 3are increasingly resistant to their effects.”' This has stimulated the search for new
antimicrobial agents with modes of action different from those of known antibiotics.
■j 4
Antimicrobial peptides are thought to be one solution to this problem.- ' Though the
mechanism of action of these peptides is still debated, there is agreement that they
2 5-2 7disrupt the cell membranes of susceptible cells. ' The reason for this selectivity is
also unclear but it has been postulated that exterior membrane charge differences,
membrane potential differences, cholesterol content and differences in the rate of
2 8-^ 12membrane repair contribute to the selective activity of the peptides. ' “' There is also
evidence that there is a distinction between antimicrobial peptides (those with direct
action against bacteria) and cytotoxic peptides. Cytotoxic peptides, as well as
2 11 2 13antimicrobial peptides, have activity against altered mammalian cells. ' ’ ' This
result is intriguing as it suggests the possibility of using cytotoxic peptides to treat 
intracellular pathogens, which are especially difficult to eliminate because conventional
2 14antibiotic therapy and the host’s immune response are ineffective. ' Brucella abortus
(Ba) and Mycobacterium tuberculosis (Mtb) are intracellular pathogens that live and
2 15replicate within the macrophages of their hosts.
29
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The veterinary pathogenic brucella species, B. abortus, B. melitensis, B. suis and B.
2 16 2 17canis are also pathogenic for man. ' ’ ' They are short, non-motile, non-sporulating
and non-encapsulated Gram-negative aerobic rods. In animals, brucella localizes in the 
reproductive organs, supramammary lymph nodes and other reticuloendothelial tissues
2 18resulting in abortion and infertility. ’ In humans, infection leads to a chronic,
2 19debilitating disease known as undulant fever. ' Human infection may result from
2 20exposure to infected animals or infected animal products. ‘ As a result, brucellosis is
an occupational hazard for veterinarians, abattoir workers, animal handlers and 
2 21laboratory staff. ' The brucella species is easily spread via aerosolization, making
2 22them good candidates for biological weapons.
Undulant fever is characterized by general malaise, fever, anorexia, muscular
2 19weakness, arthritis and dementia. ' Other disorders associated with the disease include
cardiac and neurologic disorders. If untreated, undulant fever is fatal in about 10% of
the cases. Current treatment consists of lengthy antibiotic therapy with one or more
drugs for 30 to 45 days. Relapses often occur after the treatment is stopped and the
antibiotics do not relieve the symptoms. The vaccines used to control brucellosis in
animals are not available for use in humans as they are virulent to man.
Brucella abortus is an intracellular pathogen that lives and replicates in a host’s 
2 23-2 '’Smacrophages. ‘ The ability to survive in a host’s macrophages is a key element in
2 26allowing the organism to cause disease. ' Intracellular brucellae are hidden from the
30
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immune responses of the host and are not directly exposed to the complement cascade,
7 27
neutrophils, brucella specific antibodies or conventional antibiotics.'' Brucellosis
requires alternative treatments.
Diseases caused by other intracellular pathogens would be potential targets for 
treatments developed for brucellosis. For example, the mycobacterium species of 
bacteria are intracellular pathogens that cause diseases that have etiologies similar to 
brucellosis. Mycobacterium tuberculosis, the causative agent o f  tuberculosis (Tb),
infects about a third of the world’s population and kills more people than any other
2 28infectious agent. ' Mtb is a rod-shaped, acid-fast bacterium that localizes mainly in
the respiratory systems of animals. The symptoms of tuberculosis include low-grade
fever, night sweats, fatigue, weight loss and persistent cough. Tuberculosis is spread via
2 28aerosolization of the bacteria as a result of a cough or sneeze. ' Like Ba, Mtb can live
and replicate within a host’s macrophages, making it especially difficult to treat. Current 
treatment consists of a prolonged regimen of multiple antibiotics. Many strains of 
mycobacterium now resist antibiotics, making the development of alternative treatments 
critical.
2.2 Cell Mediated Immune Responses to Intracellular Pathogens
Antimicrobial peptides have mechanisms of action different from that of 
antibiotics, thus making them interesting targets for drug design. Infection of 
mammalian cells by intracellular pathogens is particularly difficult to treat with 
conventional antibiotics alone due to the body's inability to completely eliminate the 
pathogens. In order to understand the significance of a novel mechanism of action by an
31
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antimicrobial peptide, a review of the immunology of intracellular pathogen infection is 
warranted.
One of the body’s responses to an infection is to engulf the invading bacteria 
using macrophages (M<|>). Some of the macrophages kill the bacteria and process 
bacterial antigens for display on the major histocompatibility complex (MHC). CD4+ T- 
cells differentiate into TuTH-cells (DTH = delayed-type hypersensitivity) within two to 
several weeks after infection. Figure 2.1 shows how the TDTH-cells target infected 
macrophages. The Tdth-ccIIs recognize the infected macrophages presenting the 
bacterial antigen, which results in the invasion of a large number of activated 
macrophages. The activated macrophages sequester the infection inside a granuloma 
consisting of a few Torn-cells and many activated macrophages. The macrophages may 
differentiate into epitheloid cells or multinucleated giant cells. Figure 2.2 shows the 
anatomy of a granuloma. The activated macrophages usually repress the infection. 
Cytokines produced by TDTH-cells inhibit further spread of the infection. IFN-y is 
important in the body’s response to mycobacterium infection. Knockout mice lacking 
IFN-y died even when infected with an attenuated strain of Mycobacterium sp. (Bacillus 
Calmette-Guerin). Normal mice possessing IFN-y survive this infection. Macrophages 
presenting bacterial antigens are also attacked by CD8+ T-cells that differentiate into 
cytolytic T-cells. Figure 2.3 shows the development and killing mechanism of cytolytic 
T-cells. The cytolytic T-cells release granules near the cell marked for eradication. The 
granules contain perforin monomers that oligomerize into large pores on the cell 
membrane, resulting in lysis of the cell. These immune responses are effective only 
against macrophages that process the intracellular pathogen and present bacterial
32
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antigens. Infected cells that fail to process the intracellular pathogen will harbor the
infection. The infection becomes asymptomatic after the development of
hypersensitivity in most people. Furthermore, quiescent granuloma can also harbor
2 ^9viable intracellular pathogens, especially in the case of tuberculosis.
2.3 Results
Table 2.1 lists the de novo amphipathic peptides used in this study. They are
comprised of 80% a,a-disubstituted amino acids (aaA A ’s) and a natural amino acid
residue. The design is based on antimicrobial peptides that occur in nature with the
incorporation of the aaA A ’s to promote helicity. Table 2.2 lists several naturally
occurring antimicrobial peptides. Studies have shown that amphipathic peptides with at
2 30 2 31least eighteen residues can have high cytotoxicity. ' ’ Shortening the peptides to
fourteen residues reduces cytotoxicity but maintains most of the antimicrobial
2 30 2 31activity. ' ’ The peptides under discussion were part of a series of peptides
synthesized in our lab to test the hypothesis that a-aminoisobutyric acid, Aib and Aib-
like residues would stabilize helical conformations and maintain biological activity as
2 32the peptide length was decreased. ' Various combinations of lysine with Aib, 1-
amino-l-cyclohexanecarboxylic acid, Cyh, and 4-aminopiperidine-4-carboxylic acid,
Api, were used in the peptides. Figure 2.4 shows the structures of these amino acids.
2 33-2 35The peptides were synthesized using acid fluorides developed by Carpino.
The peptides were synthesized on a Milligen 9050 peptide synthesizer using 
PAL-PEG-PS support. The reactions were carried out in N,N-dimethylformamide
33
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2Figure 2.1. Delayed-type hypersensitivity (DTH) immune response.
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Figure 2.4. Structures of Aib, Cyh and Api amino acids.
Table 2.1
Sequences of de novo peptides.
Peptide Sequence
Pi-10 Aib-Aib-Api-Lys-Aib-Aib-Api-Lys-Aib-Aib-NH2
Ipi-10 Api-Aib-Aib-Lys-Aib-Aib-Lys-Aib-Aib-Api-NH2
Cyh-10 Cyh-Cyh-Api-Lys-Cyh-Cyh-Api-Lys-Cyh-Cyh-NH2
Ich-10 Api-Cyh-Cyh-Ly s-Cyh-Cyh-Lys-Cyh-Cyh-Api-NH2
37
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Table 2.2
Sequences of naturally occurring antimicrobial peptides.
Peptide Sequence
Gly-De-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro- 
Melittin Ala-Leu-ne-Ser-Trp-ne-Lys-Arg-Lys-Arg-Gln-Gln-NH2
Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys-Met-Gly-Arg-Asn- 
Cecropin B amide ne-Arg-Asn-Gly-De-Val-Lys-Ala-Gly-Pro-Ala-Ile-Ala-Val-
Leu-Gly-Glu-Ala-Lys-Ala-Leu-NH2
Gly-De-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-lys-Phe-Gly-Lys- 
Magainin 2 amide Ala-Phe-Val-Gly-Glu-He-Met-Asn-Ser-NH2__________________
(DMF) using 8 equivalents of the 9-fluorenylmethyloxycarbonyl (Fmoc)-amino acid 
fluorides, and 3 equivalents of diisopropylethylamine (DIEA). The amino acids were 
allowed to couple for 1.5 hours. Removal of the Fmoc protecting group was done using 
a solution of 2% l,8-diazobicyclo[4.5.0]undec-7-ene (DBU), and 20% piperdine in 
DMF. Deprotection of the side chains and cleavage from the resin was accomplished
simultaneously by treatment with trifluoroacetic acid (TFA), triisopropylsilane, water,
2 36and phenol (8.8:0.2:0.5:0.5) (reagent B) for 2 hours. ' Purification of the peptides
was done by preparative reverse-phase HPLC on a C4 column using a gradient of water 
and acetonitrile with 0.05% TFA in each. Molecular weight and amino acid composition 
were verified by MALDI mass spectrometry and amino acid analysis, respectively. The 
peptides were synthesized by manually coupling the first three residues on PAL-PEG-PS 
resin using eight equivalents of the amino acid fluoride and two equivalents of DIEA in 
gently reflu xing methylene chloride (DCM). The reaction was monitored by removal of 
small aliquots o f resin followed by work-up to determine the level of Fmoc-piperidine
38
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2 37adduct present relative to the expected amounts. After the first three couplings were
completed, the remainder of the sequences was synthesized on the Milligen 9050. The 
direct antimicrobial activities of the peptides were tested against representative Gram- 
positive (S. aureus) and Gram-negative (E. coli) bacteria. Table 2.3 summarizes the 
results.
Table 2.3
Peptide antimicrobial activity.
Peptide M IC (pM) vs. E. coli MIC (pM ) vs. S. aureus
Pi-10 8 123
Ipi-10 4 Not active
Cyh-10 6 6
Ich-10 13 3
Melittin 3 3
Cecropin B amide 1 12
Magainin 2 amide 10 19
Chronically infected mice are susceptible to peptide toxicity at lower doses than 
healthy mice. For melittin, the highest non-lethal dose was 25 pg. For Aib containing 
peptides (P i-10 and Ipi-10), the highest non-lethal dose was 500 pg. For Ich-10, the 
highest non-lethal dose was 25 pg. The toxicity estimations were grouped into three 
categories: none, stress and toxic. None meant the peptide showed no apparent effect on 
the peptide-treated, non-infected mice as compared to the saline-treated infected mice.
39
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Stress was used to indicate that the mouse showed signs of distress: i.e. tremors, 
temporary paralysis, etc. Toxic meant that some of the mice in that treatment group died 
at the lowest dose that still reduced spleenic brucella levels.
Peptide doses were titrated to the lowest effective dose; however, several of the 
infected mice died at peptide doses that were harmless to the control mice. The mice 
usually died within 1-2 minutes of injection from massive internal bleeding. Table 2.4 
shows the indirect in vivo activity of the peptides against Brucella abortus in BALB/c 
mice.
Table 2.5 shows percent normal murine macrophage survival versus peptide
concentration. Pi-10 shows little toxicity at all concentrations tested while Ich-10 was
very toxic at 100 pM and less so at 10 pM. For comparison, melittin is very toxic at 10
pM. For the in vitro studies, doses that showed > 70% macrophage survival were used
as the starting dosages to determine if infected macrophages are selectively destroyed
relative to non-infected macrophages. The data is shown in Table 2.6.
Murine macrophages were incubated with B. abortus, which infects approximately 40% 
2 24of the macrophages. ‘ The survival rate (90%) of this partially infected macrophage
population was the same as the normal non-infected macrophage survival rate over a 48- 
hour period. Melittin shows slightly lower survival of infected macrophages while the 
remaining peptides show significantly lower survival of the infected macrophages. Pi-10 
shows an approximately 40% lower macrophage survival rate of the partially infected 
population. This agrees with the maximum expected since about 40% of the 
macrophages are infected. Ipi-10 and Ich-10 kill less and more than the expected ideal 
value of 40%, respectively.
40
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Table 2.4
Indirect in vivo activity against Brucella abortus in BALB/c mice.
Peptide Dose (pg) % Brucella 
Reduction
Toxicity
Pi-10 500 90 None
Ipi-10 500 55 Stress
Cyh-10 ND ND ND
Ich-10 25 82 None
Melittin 25 50 None
Cecropin B amide 500 53 None
Magainin 2 amide 500 54 None
Table 2.5
Normal macrophage survival versus peptide concentration.
Peptide 100 pM 10 pM 1 pM
Pi-10 91 96 97
Ich-10 0 77 100
Melittin ND < 2 ND
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Table 2.6
In vitro peptide toxicity against normal and infected murine macrophages.
Peptide Cone (fiM) % Survival 
Normal M<t>’s
% Survival 
Infected M<t>’s
Statistical
Significance*
Pi-10 10 90 55 S
Ipi-10 50 90 80 s
Ich-10 25 95 20 s
Melittin 0.1 85 78 s
a Independent student’s t-test at a 95% confidence level.
To test the hypothesis that these peptides selectively destroy infected 
macrophages over non-infected macrophages, in vitro studies were performed using a 
strain of Ba containing a green fluorescent protein (GFP) and a strain of Mycobacterium 
chelonei (Mch). Ba is too small to be seen at the magnification levels used to visualize 
the macrophages; therefore, the strain expressing the GFP allows the infected 
macrophages to be identified. Mch is a relatively large microorganism and is easily seen 
inside the macrophages. Table 2.7 summarizes the results using P i-10 and Ich-10.
Figures 2.5 to 2.15 are photomicrographs of the macrophages used in this portion 
of the study. Trypan blue exclusion was used to visualize dead macrophages. Figure 2.5 
is a photograph of normal, healthy macrophages. Figure 2.6 shows a fluorescence
42
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Table 2.7
In vitro peptide activity against control and infected macrophages.
Peptide Dose (pM) % Survival 
Ba Infected
M<t>
% Survival 
Mch Infected
M<(>
Statistical
Significance*
Pi-10 — 99.6 ± 0 .6 97.0 ±3.0
Ich-10 — 95.0 ± 2.0 N/A
Pi-10 100 pM 80.3 ±  3.5 72.8 ±5.1 S
Ich-10 50 pM 81.0 ±  1.0 N/A s
a Independent student's t-test at a 95% confidence level
photograph of healthy macrophages. Figure 2.7 shows a Nomarski photograph of 
macrophages infected with Ba-GFP. Figure 2.8 is a fluorescence photograph of the 
macrophages infected with Ba-G FP. Figure 2.9 shows uninfected macrophages treated 
with 100 pM Pi-10. Figure 2.10 shows a fluorescence photograph of uninfected 
macrophages treated with 100 pM Pi-10. Figure 2.11 is a Nomarski photograph of 
macrophages infected with fta-GFP and treated with 100 pM Pi-10. Figure 2.12 shows 
a fluorescence photograph of the macrophages infected with fla-GFP and treated with 
100 pM Pi-10.
To test the theory that the peptides are active against macrophages infected with a 
different intracellular pathogen, studies were carried out using Mycobacterium chelonei. 
Mch was used instead of Mtb as it is less virulent to man than Mtb. Figures 2.13 to 2.15 
show the results of this study. Figure 2.13 shows macrophages that have been infected
43
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Figure 2.5. Nomarski photomicrograph of healthy macrophages.
44
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Figure 2.6. Fluorescence photomicrograph of healthy macrophages.
45
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 2.7. Nomarski photomicrograph of untreated macrophages infected with Ba-
GFP.
46
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Figure 2.8. Fluorescence photomicrograph of untreated macrophages infected with
fla-GFP.
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Figure 2.9. Nomarski photomicrograph of treated, uninfected macrophages.
48
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Figure 2.10. Fluorescence photomicrograph of treated, uninfected macrophages.
49
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 2.11. Nomarski photomicrograph of peptide treated macrophages infected with
Ba-GFP.
50
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Figure 2.12. Fluorescence photomicrograph of peptide treated macrophages infected
with Ba-G FP.
51
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Figure 2.13. Nomarski photomicrograph of untreated macrophages infected with Mch.
52
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Figure 2.14. Nomarski photomicrograph of peptide treated macrophages infected with
Mch.
53
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Figure 2.15. Nomarski photomicrograph of peptide treated macrophages infected with
Mch which shows cell membrane disruption.
54
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with Mch. Figures 2.14 and 2.15 show macrophages infected with Mch that have been 
treated with 100 pM Pi-10.
2.4 Discussion
It is well known that basic amphipathic a-helical peptides exhibit in vitro
antimicrobial activity at pM concentrations. The hydrophobic peptides in this class
usually display high mammalian cell toxicity. A good example of this class of peptides is
melittin. It is an amphipathic peptide with a relatively narrow polar face and possesses 
2 38high cytotoxicity. ‘ De novo peptides have been designed to mimic melittin and those
containing hydrophobic and hydrophilic residues such as leucine and lysine are among
2 39the most cytotoxic known. ' It has been shown that cytotoxicity depends on the length
of the peptide as well as hydrophobicity. As the peptide length is decreased, cytotoxicity
also decreases. Our group has demonstrated this phenomenon using a series of de novo
hydrophobic, amphipathic peptides. Cytotoxicity was almost eliminated when the
peptides were shortened from 21 residues to 14 residues. Interestingly, direct in vitro
2 31antimicrobial activity was essentially retained in the shorter peptides.
Using the knowledge that shorter, more hydrophobic helical peptides could retain
biological activity with reduced cytotoxicity, it was hypothesized that otaAA’s could be
used to design shorter, helical peptides. Since ocaAA’s promote helicity, their
incorporation into very short hydrophobic peptides should lead to more selective and
2 40-2 43more biologically active peptides. ' A problem with this approach is the difficulty
associated with incorporation of aaA A ’s using conventional peptide coupling
55
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2 43reagents. ' This problem has been solved with Carpino’s development of acid
fluorides for amino acid couplings. This method allows for the mild and efficient solid-
i  33
phase synthesis of peptides containing multiple aaA A ’s. Despite the improved
coupling method, difficulties in the synthesis of the peptides were still encountered. The
second residue in P i-10, Ipi-10, Cyh-10 and Ich-10 did not couple efficiently. This is
presumably due to steric difficulties in coupling two aocAA’s together near the resin.
The problem was resolved by gently refluxing the first three couplings in methylene
chloride with DIEA. Each coupling was monitored by quantitative Fmoc tests until at
least 95% coupling efficiency was indicated. Once the third residue was satisfactorily
coupled, the remaining residues were coupled using the Milligen 9050.
A maximum number of aaA A ’s was desired in each peptide to promote helicity.
To achieve this and maintain a high number of positive charges on the polar face, the
2 33aaA A , Api, was used. A peptide consisting only of aaA A ’s would be difficult to
synthesize and would present problems in our spectroscopic studies. Since the aaA A ’s
are achiral, the resulting peptides would have no preference for a right-handed or left-
handed helix. As a result, two L-lysine residues are used in each peptide.
It has been shown that peptides that contain Aib residues are significantly more
helical than peptides that are comprised only of natural amino acids. The replacement of
natural amino acids with Aib also substantially improved antimicrobial activity against
2 31E. coli and S. aureus. Pi-10 shows a significant improvement in activity over
2 32peptides containing only proteinogenic amino acids. ' This increase in activity is
56
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attributed not only to the improved helicity but the increase in hydrophobicity that Aib 
gives the peptide. Ipi-10, a sequence permutation isomer of P i-10, shows similar 
activity. To study the effects of hydrophobicity on peptide activity, Cyh-10 and Ich-10 
were synthesized. In these peptides, the Aib residues are replaced with Cyh residues. As 
can be seen in Table 2.3, these peptides have similar activity against E. coli but are up to 
41 times more active against S. aureus.
The in vitro studies provided us with some background regarding what to expect 
in the in vivo studies. Melittin proved to be the most cytotoxic peptide in the in vitro 
studies. It is the most active peptide in vivo with effective dosages at 25 pg per mouse. 
The in vivo studies were carried out by injecting the peptides in the lateral tail vein which 
should rapidly carry the peptide to the primary site of infection, the spleen. It was 
thought that melittin would indiscriminately attack all cells in the blood but in normal, 
non-infected mice, this did not occur. However, when similar doses of melittin were 
administered to infected mice, they died within 1 to 2 minutes of injection. Necropsy of 
these mice showed massive internal bleeding with the lungs filled with blood. 
Apparently, the mice died of sepsis associated with the simultaneous lysis of a large 
number of macrophages releasing nitric oxide and cytokines. Similar behavior was 
noted for Ich-10, which is expected due to its increased hydrophobicity. An injection of 
50 pg into an infected mouse resulted in death.
The de novo peptides were tested in vitro against normal and infected murine 
macrophages. Macrophages were harvested from the spleens of normal mice and plated 
out in 96 well plates. Trypan blue exclusion was used as an indicator of macrophage 
viability. About 90% of the plated out macrophages survived the stress of this
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manipulation, so only survival percentages less than 90% indicate peptide toxicity.
These experiments were performed to determine the peptide concentrations to be used
against the infected macrophages. P i-10 and Ich-10 were tested at 1 to 100 pM. P i-10
was non-toxic at 10 pM whereas Ich-10 was non-toxic at 1 pM. Melittin is non-toxic at
0.1 pM owing to its length and hydrophobicity. The macrophages plated out as above
were infected with B. abortus for one hour. The excess brucellae were washed away
leaving behind intracellular brucellae. Brucella counts indicated that approximately 40%
of the macrophages were infected. This percentage of experimental brucellae infection is
2 20consistent with literature values. ' The macrophages had the same viability pre- and 1
to 48 hours post infection as determined by trypan blue exclusion. Peptide effects on 
macrophage survival at the doses determined above were assayed. Table 2.6 shows that 
melittin, Ich-10 and Pi-10 are effective in selectively killing infected macrophages over 
non-infected macrophages. Ich-10 and melittin are effective at much lower 
concentrations than Pi-10 presumably due to their increased hydrophobicity. Ich-10 
deviates slightly from the ideal value of 55%, suggesting that the optimal dose is lower 
than that tested.
To further test the hypothesis that the peptides selectively destroy infected over 
non-infected macrophages, the above in vitro studies were repeated using a strain of B. 
abortus containing a green fluorescent protein. In addition, in vitro studies were carried 
out using M. chelonei to verify that these peptides were effective against a different 
intracellular pathogen. Pi-10 was the only peptide used in this study since it showed the 
most selectivity for killing infected macrophages. The macrophages were harvested and 
plated out as before. Infection with Ba-GFP and Mch were also carried out as before.
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Macrophage assays reveal that a similar percentage of macrophages were infected with 
both intracellular pathogens. The intracellular brucellae are too small to visualize with 
conventional light microscopy. The Ba containing the green fluorescent protein allows 
them to be visualized inside the macrophages using fluorescence microscopy. Mch is 
large enough to be seen inside the macrophages using conventional light microscopy. 
Each study was repeated as before to show that there was no difference in using the 
normal strain of Ba vs. Ba-GFP or Mch. The data on the non-infected peptide treated 
and infected non-peptide macrophages was within experimental error of that done for 
previous studies. Figures 2.5 to 2.15 show photomicrographs of these results. The 
infected macrophages were then treated with 100 pM of P i-10 for one hour. Excess 
peptide was washed away, trypan blue was added and allowed to stand for 5 minutes. 
The excess trypan blue was removed and the macrophages were assayed. Figures 2.11 
and 2.12 show the Nomarski and fluorescence photographs of the same region of a 96 
well plate. As can be seen in Figure 2.11, the blue cells are dead. Figure 2.12 reveals 
that these cells were infected with fla-GFP, making them susceptible to the peptide. 
There appears to be several cells that exhibit fluorescence and are not dead. This may be 
the result of slight auto-fluorescence of the cell that is not infected or insufficient peptide 
dose to kili the macrophage, which is infected. Figure 2.13 reveals several macrophages 
that are infected with Mch. The bacteria appear as rod-like structures. Figures 2.14 and 
2.15 show that the macrophages possessing these organisms have been destroyed by the 
peptide, leaving other macrophages intact.
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2.5 Experimental
2.5.1 Peptide Synthesis
Cyh-10 and Ich-10 were synthesized by manually coupling the first three residues 
onto a PAL-PEG-PS solid support. The couplings were done by refluxing 8 equivalents 
of the Fmoc-acid fluoride, 3 equivalents of DIEA and the resin in methylene chloride.
The couplings were allowed to reflux until an acceptable yield was determined by
2 37quantitative Fmoc tests. ' After the first three residues were coupled to the resin, the
resin was placed on the Milligen 9050 synthesizer and the synthesis was continued. 
Eight equivalents of preformed Fmoc-acid fluorides, three equivalents of DIEA and a 1.5 
h recycling time were used for the couplings. A solution of 20% piperidine/2% 1,8- 
diazobicyclo[4.5.0]undec-7-ene (DBU) in DMF was used for Fmoc removal. The 
peptides were simultaneously cleaved from the resin and side-chain deprotected using 
reagent B (8.8:0.2:0.5:0.5, trifluoroacetic acid (TFA), triisipropylsilane, water, 
36p h e n o l ) . T h e  resulting solution was diluted with cold 30% acetic acid, washed with
diethyl ether (4 x 50 mL) and lyophilized. The crude peptides were purified by 
preparative reverse-phase HPLC on a Waters 15 pm Deltapak C4 column using a water 
(0.05% TFA) and acetonitrile (0.05% TFA) gradient system. The gradient was run from 
10% to 50% organic and the absorption was monitored at 222 nm. Peptide purity was 
verified on a Vydac 5 pm CI8 column using the same conditions. Matrix assisted laser 
desorption ionization (MALDI) mass spectrometry was used to verify peptide mass. Ich- 
10 and Cyh-10 1276 (M+H)+.
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2.5.2 Amino Acid Analysis
Amino acid analyses were performed according to reference 2.21 using a 
Beckman 6300 .Amino Acid Analyzer. In short, the peptides were hydrolyzed in 6N HC1 
and 0.01% phenol for 24 h at 110°C. The samples were analyzed on a cation exchange 
column at 65°C with post-column ninhydrin derivitization at 130°C.
2.5.3 MIC Assays
E. coli American type culture collection (ATCC) 25922 and S. aureus ATCC 
25922 were used as representative Gram-positive and Gram-negative bacteria in the MIC 
assays. The bacterial cultures were grown in nutrient broth to midlog phase and 
standardized using McFarland standard before dilution. A 512 pg/mL peptide stock 
solution was prepared and 1:2 serial dilutions were prepared and added to the culture 
media to give final peptide concentrations of 256 pg/mL.
Fifty microliters of cells (5 X 104) and 50 pL of the peptide solution were added 
to a sterile well and the MIC was determined by the lowest concentration that inhibited 
cell growth. The inhibition of cell growth was indicated by the absence of turbidity after 
four hours. Turbidity in the wells was visualized manually. The MIC values are 
reported as the median value for at least three experiments.
2.5.4 In vivo B. Abortus Studies
Stock cultures of virulent B. abortus strain 2308 were passaged in BALB/c mice 
and isolated in pure culture from spleens. Stock cultures were prepared from 48 hour 
growth on Schaedler blood agar plates and stored at -80°C. For infections, the contents 
were freshly thawed, pooled and diluted in sterile phosphate buffered saline (PBS) to a 
concentration of 5x10s colony forming units (cfu) per mL. Exact numbers were
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established by subsequent viable counts. Stock cultures for macrophage assays were
derived from the stocks above from a single solid passage.
Mice. Female B ALB/c mice were purchased at 10 weeks of age from the
Department of Laboratory Animal Medicine at the LSU School of Veterinary Medicine
breeding colony. The animals were held 1 week prior to use.
Challenge infection of mice with B. abortus and peptide treatment Mice were
infected via the lateral tail vein with approximately 5xl04 cfu of B. abortus in 100 pL of
PBS. Approximately 4-6 weeks post infection, the mice were injected with a  sublethal
dose of peptide and a control group was injected with diluent. After 24 h, the peptide
treatment group mice were sacrificed by C 0 2 asphyxiation and their spleens and livers
aseptically removed. The tissues were homogenized in 10 mL of PBS, serially diluted,
and plated in triplicate. Colonies were counted after 3 days of incubation at 37°C under
an atmosphere of 10% C 0 2. Bacterial loads in the peptide treated animals were
compared to the diluent controls.
2.5.5 In Vitro Biological Studies
Preparation of cells. Modifications of the procedures described previously were
used to harvest and infect murine resident peritoneal macrophages with B. abortus-GFP 
2 20 2and M. chelonei. ' Following euthanasia, cells were harvested by lavage from the
peritoneal cavity of ten-week old BALB/c mice using 8 mL of DMEM (Dulbecco’s 
Modified Eagle Medium) + 5% fetal calf serum (FCS). The cells were cultured in 96 
well plates at a concentration of 1.5x10s per well in 200 pL of DMEM + 5% FCS at 
37°C in 5% C 0 2. Cell cultures were enriched for macrophages by washing away non-
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adherent cells after overnight incubation with PBS + 5% FCS and 200 pL of fresh media 
was added to the cultures.
Determination of non-cytotoxic concentration of peptides. Normal macrophage 
cultures were treated with 0 to 200 pM of the test peptide. The peptides were incubated 
with the cells for 1 hour at 37°C in 5% C 0 2. The cells were washed 3 times with PBS + 
5% FCS to remove any residual peptide. Peptide treated cells were stained with 0.04% 
trypan blue in DMEM + 5% FCS. One to two hundred cells per well were counted using 
an inverted microscope and the number of stained cells was recorded. Five wells were 
examined per peptide concentration. Percent survival was calculated by subtracting the 
number of blue (dead) cells from the total cells and normalized.
Infection of cells with B. abortus-GFP and M. chelonei. B. abortus-GFP or M. 
chelonei opsonized with a sub-agglutinating dilution (1:2000) of hyperimmune BALB/c 
mouse sera in DMEM + 5% FCS was added to the macrophages at a ratio of 
approximately 100 bacteria per macrophage. Phagocytosis proceeded for 2 h at 37°C. 
Extracellular organisms were removed by washing 3 times with PBS + 5% FCS and 
fresh DMEM.
In vitro peptide treatment Using non-cytotoxic concentrations, peptides were 
added to infected and non-infected cell cultures for 1 hour at 37°C, 5% C 0 2. The cells 
were washed 3 times with PBS + 5% FCS to remove any residual peptide. Percent 
viability was determined as described above.
2.5.6 Statistical Analysis
A mean value for each spleen count was obtained by averaging the triplicate 
values. Data was expressed as percent bacterial reduction compared to the appropriate
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controls. Percent bacterial reduction was determined by subtracting the total number of
organisms in the treated spleens from the total number of organisms in the control
spleens. This difference was divided by the total number of organisms in the control
spleens and multiplied by 100. Statistical comparisons between experimental groups
were performed using the two-tailed independent Student’s t test with p values less than
2 440.05 considered significant.
2.5.7 Biological Containment and Animal Use
All procedures involving live Brucellae and Mycobacteria were performed in a 
Biological Level 3 (BL-3) containment facility at the LSU-SVM following Centers for
o 45
Disease Control/National Institutes of Health guidelines.”' In conducting research
using animals, the investigators adhered to the “Guide for the Care and Use of 
Laboratory Animals” prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National Research
„  .. 2.46Council.
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Chapter 3
Structural Studies of Peptides Rich in a,a-Disubstituted Amino Acids
3.1 Introduction
The holy grail of de novo protein design is the ability to predict secondary
3 1-3 3structure (i.e. a-helix, (3-sheet, or 310-helix) from the amino acid sequence. ' By far,
the a-helix is the most common and most studied secondary structure. Relatively little is
know n about the factors favoring form ation  o f  the 3^ -he lix .3'4"3'8 T h e  3 10-helix
comprises approximately 10% of all helical structures and is thought to be a folding
3 5 3 9-3 13intermediate to the a-helix. ' Small sections of 3i0-helices often occur in
g lobular proteins and  are  thought to  b e  im portan t in protein recognition.3'4’3' 15 Thus
efforts to study the 310-/a-helix equilibrium are important in increasing our knowledge of 
the protein folding process. Most studies exploring this equilibrium have been 
concentrated on short, hydrophobic peptides containing several a,a-disubstituted amino
acids (aaA A 's).3' 16*3' 19 As a result, spectroscopic studies of these peptides have been
limited to organic solvents such as dimethylsulfoxide (DMSO), methanol,
trifluoroethanol (TFE) and acetonitrile. Structures of these peptides have also been
3 20-3 23obtained by X -ray analysis o f  crystals g row n from  organic solvents. ' T he  a-helix
3 24*3 26
has been studied extensively in w ater and  organic solvent systems. ' Recently,
Toniolo and co-workers have reported spectroscopic studies of a peptide exhibiting 3,0-
3 27helical structure in water. ' We have synthesized a series of amphipathic, water-
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soluble peptides comprised of 80% aaA A ’s. Here we report the helical structure of 
these peptides using circular dichroism spectroscopy (CD).
3.2 Results
Each peptide was designed to form an amphipathic helix either in an a-helix or a
3,0-helix. The amphipathic helices have their charged residues along one side creating a
polar face and have their uncharged residues along the other side, creating a non-polar
3 ^8 329face. ’ Pi-10 and Cyh-10 were designed to be perfectly amphipathic as an a -
helix while Ipi-10 and Ich-10 were designed to be perfectly amphipathic as a 3l0-helix.
Figures 3.1 to 3.4 show each peptide in its amphipathic helical form as well as it’s less
perfectly amphipathic alternative form. The large percentages of aaA A ’s are used to
promote helicity. Amphipathy is used as the design tool to control which helix type is
3 30 3 31formed. All peptides were synthesized and purified as previously reported.
In CD spectroscopy, helical peptides are characterized by two minima. The
n-»7t’ transition is centered around 222 nm and the it—>n transition is centered near 207
3 32nm. ' Since both the 310- and a-helices exhibit these minima, the intensities of the
minima are used to distinguish between these helical structures. The ratio, R, where R = 
[0]n-wr>/[0]n-+jr* has been proposed as the factor to distinguish a 3i0-helix from an a-
helix. In 3t0-helices, R < 0.4 while for a-helices R = 1 3-32'3-35 Tables 3.1 to 3.4 show
the % a-helicity and R for Pi-10, Cyh-10 and Ich-10 and the % 3i0-helicity and R for 
Ipi-10 in various solvent systems. It was expected that the peptides would adopt the 
helical structure that allowed them to be most amphipathic. In SDS micelles, all
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Figure 3.1. Sequence and a - and 3I0-helical wheel diagrams of Pi-10.
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Figure 3.2. Sequence and a - and 310-helical wheel diagrams of Ipi-10.
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Figure 3.3. Sequence and a - and 3i0-helical wheel diagrams of Cyh-10.
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Figure 3.4. Sequence and a-helix and 310-helical wheel diagrams for Ich-10.
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Figure 3.5. CD Spectra of Pi-10 (A), Ipi-10 (■ ) , Cyh-10 (♦ ) and Ich-10 ( • )  in SDS 
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Figure 3.6. CD spectra of P i-10 in 1:1 CH3CN-H20  (▲), 9:1 CH3CN-H20  (♦), and 
9:1 CH3CN -TFE(B).
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Figure 3.9. CD spectra of Ich-10 in 1:1 CH3CN-H20  (▲), 9:1 CH3CN-H20  (♦), and 
9:1 CH3C N -TFE(B ).
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Table 3.1
CD data and calculated structural information for Pi- 10.a
Solvent [ e w bc R % Helicity
25 mM SDS -8750 -7930 0.90 33 (a)
9:1 CHjCN-TFE -10710 -7930 0.74 33 (a)
9:1 CH3CN-H20 -6180 -4290 0.71 22 (a)
1:1 CH3CN-H20 -3180 -2130 0.66 15(a)
a Peptide concentration was 200 pM. 
b Units for [0] are deg cm2 dm ol1.
c The minimum for the [©]*_>*• band is taken in the range from 205-209 nm. 
d The minimum for the [©]„->*• band is taken in the range from 222-225 nm.
Table 3.2
CD data and calculated structural information for Ipi-10.a
Solvent [ 0 W b’c [ 0 W bd R % Helicity
25 mM SDS -5520 -1750 0.32 25 (310)
9:1 CH3CN-TFE -9920 -3150 0.33 33 (310)
9:1 CH3CN-H20 -6740 -3610 0.54 e
1:1 CH3CN-H20 -4200 -3120 0.74 19(a)
a Peptide concentration was 200 pM. 
b Units for [0] are deg cm2 dm ol1.
c The minimum for the [0]*-+** band is taken in the range from 205-209 nm. 
d The minimum for the [0]„->if band is taken in the range from 222-225 nm. 
c In this solvent, Ipi-10 is probably a mixture of coil structures. The % a-helix is 
estimated to be 20% and the % 3i0-helix is estimated to be 31%.
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Table 3.3
CD data and calculated structural information for Cyh-10.a
Solvent [ e w bc [ e ] „ ^ bd R % Helicity
25 mM SDS -10870 -9980 0.92 39 (a)
9:1 CH3CN-TFE -10290 -9010 0.88 3 7 (a )
9:1 CH3CN-H20 -9340 -8190 0.88 3 4 (a )
1:1 CH3CN-H20 -7850 -7030 0.88 3 0 (a )
a Peptide concentration was 200 pM. 
b Units for [0] are deg cm2 dmol'1.
c The minimum for the [9]*-,*. band is taken in the range from 205-209 nm. 
d The minimum for the [0Jn_*,t. band is taken in the range from 222-225 nm.
Table 3.4
CD data and calculated structural information for Ich-10.a
Solvent [eW [e]n_>Jc.bd R % Helicity
25 mM SDS -4790 -5460 1.14 26 (a)
9:1 CH3CN-TFE -10960 -8060 0.73 33 (a)
9:1 CH3CN-HzO -6970 -6090 0.87 28 (a)
1:1 CH3CN-HzO -6770 -6580 0.97 2 9 (a )
a Peptide concentration was 200 pM. 
b Units for [0] are deg cm2 dmol'1.
c The minimum for the [0]*-**. band is taken in the range from 205-209 nm. 
d The minimum for the [0]n-«r« band is taken in the range from 222-225 nm.
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peptides, except Ipi-10, showed CD spectra characteristic of an a-helix (Figure 3.5). As 
expected, P i-10 and Cyh-10 are a-helices in all solvent systems (Tables 3.1, 3.3 and 
Figures 3.6, 3.8). Ipi-10 displays a transition from an a-helix to a 310-helix as the solvent 
system increases in organic content (Table 3.2 and Figure 3.7). It was expected that Ich- 
10 would display this same transition; however as can be seen in Table 3.4 and Figure 
3.9, this did not occur. Ich-10 displays an a-helical spectrum in all solvent systems 
tested.
The percent a-helix was estimated according to the following: percent a-helix =
-lOO([0]Mir. + 3000)/33000, where the minimum for the [0]n_*R- transition is observed in
3 29the range 222-225 nm. ' Little work has been done to quantify the percent 3i0-helix;
therefore, we have used the CD spectrum of H-(Leu-Arg-Leu)8-OH in 
diphosphatidylcholine liposomes as the model 3i0-helix. In this peptide, [0]„_>K.=-21,500
deg cm2 dmol'1 is defined as 100% 3i0-helix. ' Using this model, the above equation is
modified to estimate percent 3,0-helicity: percent 310-helix = - lOO([0]rc_,re./-21500).
3.3 Discussion
Factors stabilizing a-helices in many solvent systems have been extensively
3 36-3 38studied. ' Coil to a-helix transitions have been observed as solvent systems
3 39increase in organic content. ' A similar observation is predicted to occur for 310-
3 5helix/coil transitions. ' One factor used to favor helices over a random coil is the
incorporation of helix promoting aaA A ’s. Usually, incorporation of more than 50%
3 16-3 23aaA A ’s favors a 3i0-helix in short peptides. ' However, due to the lack of
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charged aaA A ’s, this factor has not been thoroughly studied as these studies have been
limited to organic media. With the advent of a convenient synthesis of the lysine-like
aaA A , Api, a polar aaA A  can now be readily incorporated into peptides by solid-phase 
3 30 3 31 3 40techniques. ’ ' The use of this positively charged aaAA allows the
amphipathic design element to be extended to helical, water-soluble peptides. This will 
allow CD studies to be performed on peptides in aqueous/organic solvent systems and
will allow us to probe the 3i0-/a-helix equilibrium in water, which is currently under
, . „ 3.5,3.9-3.12,3.27 debate.
In order to study the stability of the 3I0- and a-helices, one needs to be able to
distinguish between the two. It was thought that there was no difference in the CD
3 35spectra for these two secondary structures. ‘ Other techniques such as electron spin
resonance and NMR are difficult and have met with mixed results, especially with
3 5-3 8 3 41peptides containing aaA A ’s. ' ' ' Toniolo and co-workers have re-visited the
issue of using CD to resolve this issue. They conclude that the 3i0-helix has an R-value <
0.4 while the R-value for an a-helix is = 1. An additional distinguishing feature is the
positive CD band near 195 nm. This band is much weaker in the 310-helix than in the a -
helix. Toniolo shows that his CD spectra for 3i0-helices in phospholipid bilayers are in
3 32 3 33agreement with that predicted by modeling.
All peptides tested contain 80% aaA A ’s to induce helicity. Pi-10 and Ipi-10
consisted of 6 Aib residues and 2 Api residues. Cyh-10 and Ich-10 consist of 6 Cyh
residues and 2 Api residues. The remaining amino acid residue in each peptide is L-
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lysine. This natural amino acid is used to induce a right-handed helix, which will result 
in a CD signal. The lack of this amino acid would result in no circular dichroism signal 
as the peptide would have no preference for a right or left-handed helix. The L-lysines
are well seperated, near the middle of the sequence, to aid in the synthesis of the
. . 3.42, 3.43peptides.
In the peptides under study, amphipathy is the only factor used to influence the
formation of either a 3i0- or a-helix. P i-10 and Cyh-10 are designed to be a-helical
while Ipi-10 and Ich-10 are designed to be 3l0-helical. Each of these peptides is less
perfectly amphipathic in their alternative helix form (Figures 3.1 to 3.4) The peptides
showed minimal structure in water or pH 7.1-7.4, 2.5 mM phosphate buffer. Upon
addition of 25 mM SDS micelles to Pi-10, a transition to an a-helix spectrum with R =
0.90 and % a-helix = 33 % (Table 3.1 and Figure 3.5). The CD spectrum of Ipi-10 in 25
mM SDS micelles has an R = 0.32, indicative of a 310-helix (Table 3.2 and Figure 3.5).
The % 3i0-helicity is estimated to be 25%. As noted in other studies, the positive CD
3 32 3 34band near 195 nm is weaker for Ipi-10 than for Pi-10. ' ' Cyh-10 displays a typical
a-helix CD spectrum in 25 mM SDS micelles with R = 0.92 and % a-helix = 39% 
(Table 3.3 and Figure 3.5). Ich-10, which was expected to be a 3 |0-helix, exhibits an a- 
helical CD spectrum. The R-value for Ich-10 in SDS is 1.14 and % a-helix is 26%. 
Though Ich-10 is perfectly amphipathic in a 3i0-helix, it nevertheless adopted an a-helix 
structure. In the case of Ich-10, its a-helix structure is not perfectly amphipathic but it is 
still significandy amphipathic. In this form, the bulky cyclohexyl side chains on Cyh are 
further apart than in a 3 io-helix. In a 310-helix, these side chains would be in proximity.
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CD spectra of all peptides in this study were taken in solvent systems ranging 
from 100% organic to 1:1 organic/water (Tables 3.1 to 3.4 and Figures 3.6 to 3.8). Pi-10 
and Cyh-10 are typical a-helices in each solvent. Interestingly, P i-10 exhibits an 
isodichroic point near 201 nm and Cyh-10, near 205 nm. This suggests a cooperative 
helix/coil transition. An additional observation is the reduction of helicity as organic
solvent composition declines. The increase in helicity as the solvent system becomes
3 28rich in organic composition has been observed in other monomeric a-helices. ' Others
have predicted that peptides with high percentages of aaA A ’s (> 50%), such as Pi-10
3 20 3 42and Cyh-10, would be 3l0-helical. ' In addition, theoretical calculations suggest
3 5these peptides would exhibit a shift to a 3l0-helix as organic content increases. This is
not observed in our studies, suggesting that amphipathy is a significant factor in 
determining helix structure. Ipi-10 behaves as expected, displaying a weak a-helix in 1:1 
CH3CN/H20 ,  3i0-helical character in 9:1 CH3CN/H20  and stronger 3i0-helical character 
in 9:1 CH3CN/TFE. Ich-10 displays an a-helix structure in each solvent system. 
Though still a-helical, the R-value for Ich-10 is lower in 100% organic solvent than the 
other solvent systems.
The transition of Ipi-10 from an a-helix to a 3i0-helix and the lower R-value for 
Ich-10 in 100% organic solvent agrees with predictions of solvent effects on the 310-/a- 
helix equilibrium. It has been shown that peptides rich in Aib favor a 3i0-helix in less 
polar media and an a-helix in water. The increased stability of the 3 |0-helix in non-polar 
solvents is due to the extra hydrogen bond formed relative to the a-helix. It is suspected
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that a-helices are favored in water because the “extra” carbonyl and amide are able to
3 5hydrogen bond with the solvent.
For Pi-10, Cyh-10 and Ich-10, a maximum number of 7 hydrogen bonds are
possible in the a-helix conformation. For Ipi-10 in the 3i0-helical structure, 8 hydrogen
bonds are possible. Helix end effects and incomplete micelle binding tend to reduce the
3 29 3 44 3 45absolute helicity of peptides..................  In the case of Pi-10, Cyh-10 and Ich-10, the
three N-terminal amides and the two C-terminal carbonyls do not have internal hydrogen
bonding partners. For Ipi-10, the two N-terminal amides and the two C-terminal
carbonyls are without internal hydrogen bonding partners. As a result, the peptides may
3 46adopt non-ideal structures at the ends to interact with solvent. ' Recently, Toniolo and
co-workers reported a short peptide exhibiting significant 3I0-helical structure in
3 27water. ' The peptide contains the novel azacrowned functionalized amino acid, 2-
amino-3-[l-(l,4,7-triazacyclononane)] propionic acid.
As stated previously, a sufficient database of 3i0-helix structures does not yet
exist. As a result, estimation of % 310-helicity is difficult. It has been suggested that the
CD bands of a 3i0-helix will be highly dependent on the <|> and vjr torsion angles in the
peptide backbone. 3 I0-Helical peptides comprised of aaA A ’s have different 0 and y
3 20-3 23 3 32angles than 3I0-helical peptides comprised only of natural amino acids.
Toniolo and co-workers synthesized Ac-(aMeVal)8-OtBu which exhibited significant 
3 33 3 343i0-helical structure. ' Recently, Toniolo reported an additional short peptide
3 27exhibiting 3i0-helical structure in water. ' Conflicting % 310-helix content can be
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calculated based on which peptide is considered to be a definitive 310-helix. Clearly, 
more work needs to be done to resolve this issue.
3.4 Experimental
3.4.1 Peptide Synthesis
3 30 3 31Cyh-10 and Ich-10 were synthesized as previously reported. The first 3
residues were manually coupled onto PAL-PEG-PS solid support. The couplings were
done by gently refluxing 8 equivalents of the Fmoc-acid fluoride, 3 equivalents of DIEA
and the resin in methylene chloride. The couplings were allowed to gently reflux until an
3 47acceptable yield was determined by quantitative Fmoc test. After the first three
residues were coupled to the resin, the remainder of the peptide was synthesized using a
Milligen 9050 peptide synthesizer on the PAL-PEG-PS solid support using 8 equivalents
of preformed Fmoc-acid fluorides, 3 equivalents of DIEA and a 1.5 h recycling time.
Residues were double coupled when they were third in a series of a,a-disubstituted
amino acids. A solution of 20% piperidine/2% l,8-diazabicyclo[4.5.0]undec-7-ene
(DBU) in DMF was used for Fmoc removal. The peptides were simultaneously cleaved
from the resin and side-chain deprotected using reagent B (8.8 : 0.2 : 0.5 : 0.5,
3 48trifluoroacetic acid (TFA) : triisopropylsilane : water : phenol). ' The resulting acidic
solution was diluted with cold 30% acetic acid, washed with ethyl ether 94 x 50 mL), 
and lyophilized. The crude peptides were purified by preparative reverse-phase HPLC 
on a Waters 15 pM Deltapak C4 column using a water (0.05% TFA) and acetonitrile 
(0.05% TFA) gradient system. The gradient was run from 10% to 50% organic and the 
absorption monitored at 222 nm. Purity of the peptides was checked on a Vydac 5 pM
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CI8 column using the same conditions. Matrix assisted laser desorption ionization 
(MALDI) mass spectrometry was used to verify the peptide masses. Cyh-10 and Ich-10, 
1276 (M+H)+.
3.4.2 Circular Dichroism
Circular dichroism measurements were taken on a (+)-camphor sulfonic acid 
calibrated Aviv 60DS spectrophotometer at 5°C. The measurements were recorded over 
250-180 nm using a 0.1 cm pathlength quartz cell, 1 nm bandwith, 10 nm/min scan 
speed and a 5 second time constant. Background spectra were acquired prior to each 
sample spectrum and the two subtracted. Three repetitive scans were recorded and 
averaged to improve signal to noise. The reported mean residue ellipticity [0] (deg cm2 
dmol'1) is derived from the observed ellipticity, [0]obs (millidegrees), using the formula 
[0] = [0]Obs (MRW/10/c). MRW is the mean residue molecular weight of the peptide 
(molecular weight of the peptide divided by the number of peptide bonds), I is the 
pathlength (cm) and c is the peptide concentration (mg/mL).
Final peptide concentrations of 0.2 mM were used for all experiments. The 
peptides were dissolved in: trifluoroethanol for spectra taken in 9:1 CH3CN:TFE; pH
7.1-7.4, 2.5 mM phosphate buffer for spectra taken in SDS; and doubly distilled water 
for the aqueous/organic spectra. For representative aqueous/organic experiments, pH 
7.1, 2.5 mM buffer was also used as the aqueous component and the resulting spectra 
were nearly identical to the pure H20/C H 3CN spectra.
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Chapter 4
Synthesis of a Beta Sheet Promoting Amino Acid
4.1 Introduction
Next to the a-helix. the most common and readily identifiable secondary structure in 
4 1proteins is the p-sheet. ' The basic unit of a P-sheet is the P-strand, a polypeptide that
is almost fully extended. This extended conformation is not particularly stable because
there are no favorable intra-strand interactions as are found in the a -  and 3i0-helices.
The P-strand is stabilized when it is incorporated into a P-sheet, where hydrogen bonds
are formed between the peptide groups on adjacent strands. Adjacent strands can be
parallel or anti-parallel. Figures 4.1 and 4.2 show each of these structures. Anti-parallel
sheets are thought to be more stable than parallel sheets although this is not always the
case. Side chains from adjacent residues of the same strand protrude from opposite sides
of the sheet and do not interact with each other, but they can have significant interactions
4 1with the side chains of neighboring strands.
The study of the P-sheet has recently gained interest due to the suspected
involvement of the P-sheet in diseases such as Alzheimer’s disease (AD), Creutzfeldt-
Jacob disease (CJD) and bovine spongiform encephalopathy (mad cow disease). Despite
the fact that the P-sheet occurs almost as often as the a-helix among secondary
structures found in proteins, relatively little is known about the factors that stabilize the
P-sheet. The synthesis of small peptides to study the P-sheet structure has proven
elusive. Often, these peptides have a propensity to self-associate into large, generally
4 2 4  3insoluble, quaternary P-sheet structures. ’ As a result, most recent studies have
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Figure 4.1. Parallel beta sheet.
Figure 4.2. Anti-parallel beta sheet.
focused on synthesizing a novel amino acid which serves as a (3-tum to nucleate P-sheet 
formation. These P-sheet structures are intramolecular and are not a completely regular 
structure because segments of the peptide that connect the strands (i.e. turns) must adopt
4 1 4 4  4 5
different conform ations...............  Therefore, it would be beneficial to assemble a (3-
sheet that is intermolecular. The strands are not covalently linked and would be free to 
aggregate to form the P-sheet. No alteration of conformation would be needed to 
accommodate the amino acid making the turn. One problem with this approach is the 
possibility of large-scale aggregation. Too many strands aggregating to form the p-sheet
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could lead to an insoluble protein. This problem could be avoided if the p-sheet could be
limited to a small number of strands, possibly as little as two strands.
A two-stranded P-sheet has two distinctly different amide hydrogen and a -
carbon hydrogen environments. The endo amide hydrogens, labeled Ha in Figure 4.3,
form an inter-strand hydrogen bond (H-bond) to complementary amide oxygens. The
endo a-carbon pro-R position, labeled Hb is sterically congested by a convergent Hb from
the anti-parallel strand. Therefore, only a proton is tolerated in that position. The exo
amide hydrogen, labeled He, lacks a specific complementary hydrogen bond partner and
could be replaced without disruption of the two-stranded P-sheet. Doig and co-workers
have replaced the Hc-like hydrogens of a three-stranded p-sheet with methyl groups,
4 6thereby preventing further H-bond mediated oligomerization. ' Figure 4.3 also shows
that the exo a-carbon pro-R position, labeled Hd, is not sterically congested so this 
position can also be substituted without disruption of the two-stranded P-sheet. 
Replacement of He and Hj with cyclic tethers should stabilize two-stranded p-sheet 
model systems as shown in Figure 4.4.
P f  .Ho Ho Of Ho Ha Of Ho Ha o f  Ho Ha o f
h/  Hb o  r' ,Ha Hb p  r'  Ha Hb7 O R Ha Hb O R Ha HbI 4 « 4 t * t 4 /
6 «  Hb ,Ha /  R Hb H'a 6  R ^  Ha 6  R Hb Ha 6  RK,
He °  Hd R He o Hd=, Hc O H ^  O Hc
Figure 4.3. Two stranded beta sheet with exo and endo positions shown.
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Figure 4.4. Two stranded beta sheet with cyclic tether shown.
Most de novo (3-sheet models use natural or artificial (3-tums or linkers to  initiate
4 6-4 12intramolecular p-sheet dimers. ' By incorporating lactam-constrained amino acids
as well as a-amino acids, it should be possible to synthesize a peptide that is pre­
organized to have extended-like conformations. Unlike the hairpin model systems 
discussed above, these individual extended conformation strands should spontaneously 
self-assemble into p-sheet dimers when a minimum peptide length is reached. The use 
of lactam-constrained amino acids, like Doig’s approach, should inhibit further H-bond 
mediated oligomerization because the amide Hc atoms are replaced.
In order to determine the correct tether for the lactam-constrained amino acid, 
selected distances in several peptides having protons in Hc- and Hd-Iike environments 
were measured using Sybyl. The average distance between He and Hd is 2.25 A . Plane 
angles were then calculated from the HN-amide and pro-R a-CH-carbonyl. The relative 
plane angle differences were between 12° to 20°. The ith C-Hd and /th + 1 H-Nc are held 
close to parallel to each other in the extended conformation. The distance between the 
ith C-H<i and /th + 1 N-Hc bonds is almost perfectly spanned by a 3-carbon tether, 
resulting in a six-membered lactam-constrained dipeptide (Figure 4.5).
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H
OH
Figure 4.5. Six-membered lactam-constrained dipeptide amino acid.
It is important to note the replacement of the pro-/? Hd position with a 3-carbon
tether requires the D-amino acid configuration. Pro-5 amino acid side chains alternate
pointing up and down in the /th +1 and ith constrained lactam amino acids in Figure 4.4.
In the proposed model, the hydrogen is pointing down in the /th pro-5 amino acid
position and pseudo axial on the six-membered lactam. The sterically larger amino
group occupies a pseudo equatorial position on the six-membered lactam. This
configuration should favor the extended conformation in peptides incorporating the
proposed constrained lactam amino acid.
The control of conformation with six-membered rings is well documented. The
earliest known synthesis of a lactam-constrained amino acid was reported by Freidinger 
4 13and co-workers. ‘ He reports the synthesis of a glycine-like six-membered lactam- 
constrained dipepdde derivative (Figure 4.6A). Others have since worked to synthesize
4 14-4 18
similar lactam-constrained dipeptide amino acids for study. ' Zydowsky and co-
workers synthesized glycine- and phenylalanine-like lactam-constrained dipepdde amino
acids that were a,a-disubstituted at the a-carbon of the lactam (Figure 4.6B). They
further report modest coupling yields of the amino acids (68-92%) in the synthesis of a 
4 19peptide dimer. ' Moss and co-workers report the synthesis of a ureido-based
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peptidomimetic inhibitor of a herpes simplex virus enzyme. Their inhibitor contains a
lactam-constrained dipepdde amino acid. However, the synthesis of the lactam-
constrained dipepdde amino acid involves a lengthy and expensive procedure to obtain
4 20an aldehyde intermediate. ' Here we report an improved route to a novel lactam-
constrained amino acid that is incorporated, in high yields, in a peptide pre-designed to 
form a P-sheet dimer.
H2N i f "
,co2h
Ph
,co2h
R = methyl or methylphenyl
B
Figure 4.6. Freidinger (a) and Zydowsky (b) constrained lactam amino acids.
4.2 Results and Discussion
The general structure of the target amino acid is shown in Figure 4.5. The amino
acid is constructed from a six-membered ring backbone previously shown to promote an
4 13extended conformation. ' Specifically, we sought to synthesize the valine derivative of
a constrained dipeptide amino acid (Figure 4.7) because valine is known to promote the 
4 21-4 23P-sheet structure. ‘ The valine moiety is introduced via a reductive amination.
The reductive amination step is likely adaptable to constrained dipeptide amino acids.
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Figure 4.7. Target constrained dipeptide amino acid.
The key to the synthesis of the constrained dipepdde amino acid unit (DPU) is
the synthesis of an a-amino acid semialdehyde. The synthesis of the aldehyde is based
4 24on a synthetic route developed by Martin and co-workers. ' Figure 4.8 outlines the
steps involved in the aldehyde synthesis. The synthesis begins with the esterification of 
D-glutamic acid, 4.1, with dry allyl alcohol, under argon, in the presence of 
trimethylsilylchloride (TMS-C1, 4.4 equivalents) to yield the diester after 3 days. 
Triethylamine (6.5 equivalents) and Boc anhydride (1.1 equivalents) were added 
sequentially and the reaction mixture was stirred overnight. Removal of the allyl alcohol 
followed by trituration with diethyl ether and filtration through a celite pad gave 
compound 4.2 in quantitative yield. The presence of the product was verified by FAB- 
MS (328, M+H*). In addition, 'H  NMR and l3C NMR verified the presence of the Boc 
and allyl groups by appearance of t-butyl and allyl protons and carbons, respectively. 
This reaction is versatile in that the scale can be varied greatly (1 gram to 15 grams) with 
little effect on purity or yield.
4 20The a-nitrogen in 4.2 is still quite nucleophilic, especially towards an aldehyde.
As a result, the nitrogen must be doubly protected prior to introduction of the aldehyde.
A simple way to achieve this protection is to introduce another Boc group. Compound
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4.2 is dissolved in dry acetonitrile along with N, N-dimethylaminopyridine (DMAP, 0.2 
equivalents) followed by Boc anhydride (1.1 equivalents). After two hours, an additional 
0.2 equivalents of DMAP and 0.5 equivalents of Boc anhydride are added. The red 
solution is allowed to stir overnight, after which the solvent is removed. The residue is 
taken up in a minimum volume of hexanes/ethyl acetate (7:3) and is purified via flash 
column chromatography over silica gel to give 4.3 in 95% yield. The presence of the 
product was verified by FAB-MS (428, M+FP). The product was also verified by a 
slight change in the chemical shift of the protons and carbons in the Boc group as 
determined by 'H and l3C NMR.
With the fully protected D-glutamic acid, the key aldehyde intermediate can be 
synthesized. Compound 4.3 is dissolved in dry diethyl ether under argon. Diisobutyl 
aluminum hydride (DIBAL, 1.0M solution in hexanes, 1.5 equivalents) is added drop 
wise at -78° C. The reaction is stirred at -78° C for 30 minutes at which time it is 
quenched with methanol and 10% sodium bisulfate. After extraction with 10% sodium 
bisulfate, the organic layer is dried and evaporated to give 4.4 in 98% yield. The 
presence of the product was verified by FAB-MS (372, M+H+). The product was further 
verified by the disappearance of one group of allyl protons and carbons and the 
appearance of the characteristic aldehyde proton and carbon as shown in ‘H and l3C 
NMR.
It should be noted that the selective reduction of only the side-chain ester is vital to the
success of this synthetic scheme. DIBAL is a common reagent used in the reduction of
esters to aldehydes. Martin and co-workers reported the selective reduction of the side-
4 24chain methyl ester over the mam chain ester. However, great care had to be taken to
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limit the reaction time to 5 minutes so as not to reduce the main chain ester as well. In
addition, the temperature must be kept at -78° C or over reduction to the alcohol will 
4 24result. ‘ The stability of the aluminum-oxygen complex at this temperature is the key
in the reduction to the aldehyde. Premature release of the aldehyde as a result of the
collapse of the aluminum-oxygen complex will result in reduction to the alcohol in the
presence of hydride. Initially, we sought to repeat Martin’s technique by synthesizing
the fully protected dimethyl ester of D-glutamic acid. The synthesis was easily
accomplished and variations in the conditions of the selective ester reduction confirmed
its extreme sensitivity towards over reduction. We encountered difficulties in
hydrolyzing the methyl ester, the next step in our synthetic scheme to the DPU. At this
point, we decided to make the diallyl ester instead. The selective reduction was carried
out as before and we were pleasantly surprised to discover that it was much more robust
than previously observed. The reduction time can be extended and the temperature
can be varied without any apparent over reduction. We believe the allyl ester provides
additional steric hindrance on the main chain ester resulting in exclusive attack of the
DIBAL on the side- chain ester.
With the fully protected semi-aldehyde in hand, the synthetic route of the
constrained dipeptide amino acid can be altered to accommodate virtually any amino
4 25acid via reductive amination. ' In our case, we chose to use L-valine to continue the
synthesis (Figure 4.9). Compound 4.4 and L-Val-OtBu-HCl (1 equivalent) were stirred 
in dry 1,2-dichloroethane (DCE). Triethylamine (TEA, 1.1 equivalents) was added 
followed by sodium triacetoxyborohydride (1.4 equivalents). The solution was stirred
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OH
OH
1) TMS-C1 
Allyl alcohol
2) Et3N, Boo>0
HN
4.1 4.2
B oc20 ,  DMAP 
CH3CN
(B o c )2N
DIBAL
H
4.4 4.3
Figure 4.8. Synthetic route to the key aldehyde intermediate.
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overnight, after which it was washed with saturated sodium bicarbonate. The organic 
layer was dried and evaporated to provide 4.5 in 90% yield. The presence of the product 
was verified by FAB-MS (529, M+H*)- In addition, *H and 13C revealed the presence of 
the valine side-chain methyl groups as well as the t-butyl ester.
Cyclization of 4.5 will yield the constrained dipeptide amino acid. In order to 
accomplish this step, the allyl ester must be removed. Acid hydrolysis of the ester is not 
prudent, as the t-butyl ester on the valine moiety will also be removed. Base hydrolysis 
proved to be too slow to be feasible. A logical alternative is the palladium-catalyzed
removal of allyl groups.4' ^ ’ 4‘^  Compound 4.5 is dissolved in dry dichloromethane
(DCM) under argon. Morpholine (10 equivalents) is added, followed by palladium 
tetrakistriphenylphosphine (0.1 equivalents). After 30 minutes, the reaction mixture is 
washed with IN hydrochloric acid and the organic solvent is dried and removed. The 
crude product is taken up in ethanol/DCM (9:1) and purified by flash column 
chromatography to give 4.6 in 85% yield. The presence of the product is verified by 
FAB-MS (490, M+FT)- Further evidence of the removal of the allyl ester is provided by 
the absence of the allyl protons and carbons as shown in ‘H and 13C NMR spectra of the 
product.
Compound 4.6 can be cyclized to the constrained dipeptide amino acid by an 
intramolecular amide bond formation. Compound 4.6 is dissolved in dry acetonitrile to 
which is added HATU (1 equivalent) and diisopropylethylamine (DIEA, 2.1 
equivalents). After stirring for 2 hours, the solvent is removed, the residue taken up in 
DCM and washed with 10% sodium bisulfate. The DCM is dried and evaporated to 
yield 77% of cyclized product, 4.7. The presence of the product is verified by FAB-MS
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(472, M+H*) as well as an X-ray crystal structure of the product (Figure 4.10). Tables 
4.1 to 4.3 give the bond distances, bond angles and torsion angles, respectively for 4.7. 
The angle in 4.7 is 150.3°, which compares favorably to the ideal angle of 135° in an 
antiparallel P-sheet.
The Boc protecting groups and t-butyl ester must be removed in order to prepare
the DPU for coupling. This is easily accomplished by treating 4.7 with approximately 5
mL of DCM/TFA (1:1) for 15 minutes. The DCM/TFA mixture is then removed under
vacuum. To prepare the amino acid for coupling, the a-nitrogen must be protected. A
convenient protecting group is the Fmoc group. Two routes have been utilized to
introduce this protecting group. Figure 4.11 shows both synthetic routes. The first is a
4 28method used by Lapatsanis and co-workers. ' In this method, the residue is taken up
in sufficient 9% sodium carbonate to give a solution with pH 9. The reaction mixture is 
cooled to 0° C and a solution of Fmoc-OSu (1.05 equivalents) in dioxane is added. After 
stirring for 2 hours, the reaction mixture is diluted with water and extracted with diethyl 
ether followed by ethyl acetate. The aqueous phase is cooled in an ice bath and acidified 
to pH 2 with concentrated hydrochloric acid. The Fmoc-protected amino acid is 
extracted with ethyl acetate, which is then dried and evaporated. The crude product is 
purified by flash column chromatography to give 4.8 in 51% yield. The presence of the 
product is verified by FAB-MS (437, M+H*). Proton and carbon NMR spectra verify 
the removal of the Boc groups and the t-butyl ester. The Fmoc protecting group is 
verified by the appearance of aromatic hydrogens and carbons in the respective spectra. 
An alternative procedure to introduce the Fmoc protecting group was developed by Bolin
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4 29and co-workers. ’ The residue from the Boc-group and t-butyl ester removal is
suspended in DCM. TMS-C1 (2.5 equivalents) is added to the ice cooled reaction 
mixture followed by DIEA (3.0 equivalents) and Fmoc-CI (1.1 equivalents). This 
procedure is convenient as it solubilizes the amino acid by neutralizing the free amino 
function with DDEA and forms the silyl ester with TMS-C1 in neat organic media. The 
neutral, organic-soluble amino acid is reacted with Fmoc-CI to yield the protected 
amino acid. The product is purified via silica gel chromatography to give 4.8 in 85% 
yield.
With the fully protected constrained lactam amino acid in hand, a peptide designed 
to prefer an extended conformation can now be synthesized. The peptide under study, 
Ac-Lys-Lys-Lys-DPU-DPU-Lys-Lys-NH2, was assembled using a Milligen 9050 peptide 
synthesizer on PAL-PEG-PS solid support. The couplings were done in N, N- 
dimethylformamide (DMF) using a four-fold excess of the Fmoc-amino acids, three 
equivalents of DIEA, four equivalents of HATU and a one-hour recycling time. Fmoc 
removal was accomplished by treatment with a solution of 2% 1,8-
diazobicyclo[4.5.0]undec-7-ene (DBU), 20% piperidine in DMF. Acetylation of the 
peptide was carried out by treating the resin bound peptide with a 0.2M solution of acetic 
anhydride in 0.28M DIEA solution in DMF for 40 minutes. Side-chain and resin 
cleavage was done by treatment with TFA, triisopropylsilane, water, phenol
4 30(8.8:0.2:0.5:0.5) (reagent B) for 2 hours. ' The peptide was purified by preparative
reverse-phase HPLC on a C4 column using a gradient of water and acetonitrile with 
0.05% TFA in each. Molecular weight and amino acid composition were verified by
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
H4 .4
TEA, DCE
HN
'OtBu
4.5
Pd(PPh3)4
Morpholine
DCM
N
OtBu
O
HATU. DIEA
CH3CN
OH
HN
'OtBu
4.7 4.6
Figure 4.9. Synthetic route to Boc-protected constrained lactam amino acid.
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Table 4.1
Bond distances (A) for 4.7.a
Atom 1 Atom 2 Distance Atom 1 Atom  2 Distance
Ol Cl 1.213(2) Cl C2 1.522(2)
0 2 CIO 1.317(3) C2 C3 1.527(3)
02 C l l 1.484(3) C3 C4 1.504(4)
03 CIO 1.201(3) C4 C5 1.499(3)
0 4 C15 1.319(3) C6 C l 1.534(5)
0 4 C16 1.470(3) C6 C20 1.526(4)
05 C15 1.201(3) C7 C8 1.523(4)
0 6 C20 1.324(4) C l C9 1.528(5)
0 6 C21 1.480(6) C ll C12 1.519(5)
07 C20 1.189(4) C ll C13 1.468(4)
N1 C l 1.361(3) C ll C14 1.511(4)
N1 C5 1.471(3) C16 C17 1.506(5)
N1 C6 1.453(2) C16 C18 1.497(5)
N2 C2 1.463(3) C16 C19 1.513(4)
N2 CIO 1.404(3) C21 C22 1.510(1)
N2 C15 1.389(3) C21 C23 1.563(6)
aNumbers in parentheses are estimated standard deviations in the last digits.
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Table 4.2
Bond angles (°) for 4.7 .a
Atom 1 Atom 2 Atom 3 Angle Atom 1 Atom 2 Atom 3 Angle
CIO 0 2 C ll 121.3(2) C6 C l C9 111.4(2)
C15 0 4 C16 121.6(2) C8 C l C9 127.1(2)
C20 0 6 C21 123.8(3) 0 2 CIO 03 127.1(2)
Cl Nl C5 123.9(2) 0 2 CIO N2 111.6(2)
Cl N1 C6 118.7(2) 0 3 CIO N2 121.2(2)
C5 Nl C6 117.0(2) 0 2 C ll C12 102.4(2)
C2 N2 CIO 115.9(2) 0 2 C ll C13 111.1(2)
C2 N2 C15 117.2(2) 0 2 C ll C14 108.9(2)
CIO N2 C15 126.8(2) C12 C ll C13 111.3(3)
Ol Cl Nl 122.3(2) C12 C ll C14 110.3(2)
Ol C l C2 120.2(2) C13 C ll C14 112.3(3)
N1 Cl C2 117.3(2) 0 4 C15 05 126.3(2)
“Numbers in parentheses are estimated standard deviations in the last digits.
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Table 4.2 (cont’d)
Atom I Atom 2 Atom  3 Angle Atom 1 Atom 2 Atom 3 Angle
N2 C2 Cl 109.7(2) 0 4 C15 N2 111.6(2)
N2 C2 C3 113.0(2) 0 5 C15 N2 121.9(2)
C2 C3 C4 109.9(2) 0 4 C16 C18 102.2(2)
C3 C4 C5 108.6(2) 0 4 C16 C19 108.6(2)
N l C5 C4 113.8(2) C17 C16 C18 113.2(2)
Nl C6 C l 114.0(2) C17 C16 C19 109.8(3)
N l C6 C20 108.0(2) C18 C16 C19 111.3(3)
C l C6 C20 112.6(2) 0 6 C20 0 7 124.7(3)
C6 C l C8 110.5(3) 0 6 C20 C6 110.4(3)
0 7 C20 C6 124.8(3) 0 6 C21 C23 106.4(5)
0 6 C21 C22 99.0(5) C22 C21 C23 107.0(5)
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Table 4 3
Torsion angles (°) for 4.7.a
Atom 1 Atom 2 Atom 3 Atom 4 Angle
C ll 0 2 CIO 03 1.28(0.33)
C ll 0 2 CIO N2 -175.31(0.17)
CIO 0 2 C ll C12 178.42(0.21)
CIO 0 2 C ll C13 -62.62(0.31)
CIO 0 2 C ll C14 61.57(0.27)
C16 0 4 C15 05 -8.58(0.31)
C16 0 4 C15 N2 175.24(0.17)
C15 0 4 C16 C17 58.21(0.29)
C15 0 4 C16 C18 179.37(0.23)
C15 0 4 C16 C19 -62.93(0.29)
C21 0 6 C20 07 4.48(0.57)
C21 0 6 C20 C6 -174.12(0.33)
C20 0 6 C21 C22 -171.81(0.48)
C20 0 6 C21 C23 -60.97(0.57)
C20 0 6 C21 C24 64.13(0.58)
C5 N1 Cl Ol 172.66(0.21)
C5 N1 Cl C2 -11.78(0.32)
C6 N1 Cl Ol 0.36(0.33)
aNumbers in parentheses are estimated standard deviations in the last digits.
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Table 4.3 (cont’d)
Atom 1 Atom 2 Atom 3 Atom 4 Angle
C6 N1 C l C2 175.92(0.21)
Cl N1 C5 C4 27.59(0.33)
C6 N1 C5 C4 -159.99(0.23)
Cl N1 C6 C7 106.98(0.24)
Cl N1 C6 C20 -127.04(0.23)
C5 N1 C6 C l -65.85(0.27)
C5 N1 C6 C20 60.13(0.30)
CIO N2 C2 Cl -47.58(0.23)
CIO N2 C2 C3 82.25(0.22)
C15 N2 C2 Cl 131.26(0.18)
C15 N2 C2 C3 -98.91(0.22)
C2 N2 CIO 02 151.48(0.17)
C2 N2 CIO 03 -25.34(0.28)
C15 N2 CIO 0 2 -27.23(0.27)
C15 N2 CIO 03 155.94(0.20)
C2 N2 C15 0 4 156.79(0.16)
C2 N2 C15 05 -19.58
CIO N2 C15 04 -24.51(0.26)
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Table 4.3 (cont’d)
Atom 1 Atom  2 Atom 3 Atom  4 Angle
CIO N2 C15 0 5 159.12(0.19)
Ol Cl C2 N2 -34.09(0.27)
Ol C l C2 C3 -162.77(0.20)
N1 Cl C2 N2 150.25(0.19)
N1 Cl C2 C3 21.57(0.29)
N2 C2 C3 C4 -173.99(0.20)
Cl C2 C3 C4 -46.94(0.28)
C2 C3 C4 C5 61.24(0.28)
C3 C4 C5 Nl -51.48(0.29)
N1 C6 C l C8 -169.13(0.22)
N1 C6 C l C9 -46.98(0.26)
C20 C6 C l C8 67.32(0.29)
C20 C6 C l C9 -170.52(0.22)
N1 C6 C20 0 6 58.24(0.31)
N1 C6 C20 0 6 -120.36(0.33)
C l C6 C20 0 6 -174.93(0.24)
C l C6 C20 0 7 6.47(0.41)
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1) TFA/DCM (1:1)
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3) Fmoc-OSu. Dioxane
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1) TFA/DCM (1:1)
2) TMS-C1. DIEA. 
Fmoc-Q
FmocN
4.7 4.8
Figure 4.11. Synthetic routes to Fmoc protecting group introduction.
MALDI mass spectrometry and amino acid analysis, respectively. Figures 4.12 to 4.14 
are representative examples of crude analytical and preparative scale HPLC 
chromatograms. Figure 4.15 shows the chromatogram of the purified peptide run on a 
C18 column. It should be noted that throughout the HPLC process, multiple peaks 
containing exact masses were obtained. We believe that this is indicative of peptide 
aggregation on the HPLC columns. Figures 4.16 and 4.17 show MALDI mass spectra of 
the crude and pure peptide, respectively.
Once the peptide was purified, circular dichroism spectroscopy was used to determine 
which secondary structure, if any, was present. Specifically, we were looking for a (3-
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sheet structure. (3-Sheet peptides exhibit a minimum near 217 nm and a maximum near 
195 nm representing n—»re* and iz—>n transitions, respectively. CD spectra were 
acquired in a variety of solvent conditions: 100% trifluoroethanol and 7mM phosphate 
buffer (at several pH’s) to determine the solvent effect on secondary structure. In 
addition, the concentration of the peptide was varied from 50 pM to nearly 300 mM to 
see if there was a concentration dependence on structure. Representative CD spectra are 
shown in Figure 4.18. At relatively low peptide concentrations (50 to 500 pM), the 
peptide adopted a random coil conformation, regardless of solvent, pH or peptide 
concentration (Figures 4.20 and 4.21). In a random coil, a peptide exhibits a minimum 
near 197 nm (re—»re*) and a maximum near 217 nm (n—»re*). At relatively high peptide 
concentrations, no useful CD spectra were obtained; however, as the peptide 
concentration was lowered, a return to a random coil spectrum was observed (Figure 
4.19). Clearly, a (3-sheet dimer was not obtained using this peptide. It is possible that 
the large number of lysine residues relative to the number of DPU residues could disrupt 
the dimer formation due to the positive charge on the side-chain amino groups. 
However, when the pH was adjusted above the pKa of these amino groups, no observable 
shift to a (3-sheet structure was observed. Another possibility is that the minimum 
number of DPU residues needed to nucleate (3-sheet dimer formation has not been 
reached. If this were the case, other peptides would need to be synthesized, with 
increasing numbers of DPU residues, until the P-sheet dimer is observed. An interim 
solution would be to synthesize a small peptide that incorporates a P-tum. This would 
result in the formation of an intramolecular dimer rather than the desired intermolecular
dimer, but it would provide useful information to characterize the p-sheet dimer.
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Figure 4.12. Analytical scale HPLC chromatogram of crude target peptide 
prior to ether wash.
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Figure 4.13. Analytical scale HPLC chromatogram of crude target peptide.
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Figure 4.14. Preparative scale HPLC chromatogram of crude target peptide.
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Figure 4.15. Analytical scale HPLC chromatogram of pure target peptide.
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Figure 4.16. MALDI mass spectrum of crude target peptide.
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Figure 4.17. MALDI mass spectrum of pure target peptide.
5 - i
-5 -
- 1 0 -
-15x10'
190180 230 250200 210 220 240
Wavelength (nm)
Figure 4.18. CD spectra of target peptide (200pM) in TFE (•), pH 7 phosphate buffer 
(■), pH 10 phosphate buffer (A ) and pH 10.5 phosphate buffer (♦).
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Figure 4.19. CD spectra of target peptide in water at 280mM (• ) , 140mM (■), 
50mM (A ), 25mM (▼), 12mM (♦), 6mM (o), 3mM (□).
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Figure 4.20. CD spectra of target peptide in TFE at 595pM (A ), 297pM (■), 200pM 
(•)■
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Figure 4.21. CD spectra of target peptide in pH 10.5 phosphate buffer at 400pM (♦), 
350pM (▼), 300pM (▲), 250pM (■), 200pM (•).
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4.3 Experimental
o
HN
OH 1) TMS-C! 
A lly l a lc o h o l
OH
4.1 4 .2
4.3.1 diallyl (R)-2-/erf-butoxycarbonylaminopentanedioate (4.2)
To an ice cold stirred suspension of D-glutamic acid (4.1) in dry allyl alcohol 
(150 mL) was slowly added TMS-C1 (17.3 mL, 136 mmol, 4.4 equiv.). After the 
addition was completed, the ice bath was removed and the reaction was stirred at room 
temperature for three days. Triethylamine (31 mL, 221 mmol, 6.5 equiv.) and Boc20  
(8.2 g, 37.4 mmol, 1.1 equiv.) were added sequentially and the reaction mixture was 
stirred overnight. The solvent was removed under reduced pressure, the residue 
triturated with ethyl ether and filtered through a Celite pad. The solvent was evaporated 
yielding a yellow oil as the pure product (11.1 g, 100%). 'H NMR (250 MHz, CDC13) 8 
1.43 (s, 9H), 1.99 (m, 2H), 2.19 (m, 2H), 2.47 (m, 1H), 4.58 (d, 2H), 4.63 (d, 2H), 5.29 
(m, 4H), 5.55 (d, 1H), 5.90 (m, 1H), 5.92 (m, 1H). l3C NMR (62.5 MHz, CDC13) 5 
27.19, 28.03, 30.01, 52.76, 64.95, 65.58, 79.41, 117.92, 118.38, 131.48, 131.94, 155.24, 
171.66, 172.03. FAB-MS 328 (M+H)+.
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B ocN
4  Jl 4 3
4.3.2 diallyl (2R)-2-Ar-[bis (terf-butyDoxycarbonyi]amino}-pentanedioate (4.3)
To a stirred solution of 4.2 (5 g, 15.3 mmol) and DMAP (379 mg, 3.1 mmol, 0.2 
equiv.) in dry acetonitrile (50 mL) was added Boc20  (3.67 g, 16.8 mmol, 1.1 equiv.) at 
room temperature. After two hours, an additional 1.35 g Boc20  and 379 mg DMAP 
were added and the red solution was allowed to stir overnight. The solvent was removed 
under reduced pressure and the residue taken up in hexanes/ethyl acetate (7:3). The 
crude product was purified by flash column chromatography to yield the pure product, 
4.3, as a yellow oil (6.17 g, 95%). 'H NMR (250 MHz, CDC13) 6  1.49 (s, 18H), 2.20 (m, 
2H), 2.45 (t, 1H), 2.50 (m, 2H), 4.58 (d, 2H), 4.61 (d, 2H), 5.28 (m, 4H), 5.88 (m, 1H), 
5.93 (m, 1H). ,3C NMR (62.5 MHz, CDC13) 8  25.05, 28.08, 30.86, 57.52, 65.34, 65.88, 
83.43, 118.27, 118.33, 131.86, 132.31, 152.11, 170.15, 172.44. FAB-MS 428 (M+H)+. 
Anal, calcd for C2,H33N 0 8: C, 59.02; H, 7.73; N, 3.28. Found: C, 59.18; H, 7.70; N, 
3.45.
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DIBAL
Et->0. -78° C
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4 3 4.4
4.3.3 allyl (2R)-2-Ar-[bis (/irf-butyl)oxycarbonyl]-ainino}-5-oxopentanoate (4.4)
A solution of 4.3 (1 g, 2.34 mmol) in dry EtzO was cooled to -78° C. DEBAL 
(3.51 mL, 1.0M in hexanes, 3.51 mmol, 1.5 equiv.) was slowly added over 10 minutes. 
The reaction was stirred for 30 minutes after the addition was completed and quenched 
with methanol (4 mL) and 10% NaHS04 (2mL). The mixture was stirred at room 
temperature for 30 minutes then extracted with 10% NaHS04 and the solvent evaporated 
to yield the product, 4.4, as a yellow oil (0.84 g, 98%). 'H  NMR (200 MHz, CDC13) 5 
1.49 (s, 18H), 2.18 (m, 2H), 2.54 (m, 2H), 2.56 (t, 1H), 4.62 (m, 2H), 4.91 (m, 1H), 5.27 
(m, 2H), 9.78 (t, 1H). 13C NMR (50 MHz, CDC13) 5 22.45, 28.09, 40.61, 57.55, 65.93, 
83.57, 118.34, 131.84, 152.16, 170.07,201.01. FAB-MS 372 (M+H)*'.
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4.3.4 tert- butyl (2S)-2-/V-1-[(5-ally lcarboxy la te)-(4R)-bis(JV', N'-tert-
butyloxycarbonylamino)pentyl]-2-amino-3-methyl-butanoate (4.5)
Compound 4.4 (2 g, 5.39 mmol) and L-valine-OtBu (1.13 g, 5.39 mmol, 1 equiv.)
were dissolved in dry DCE (100 mL) under argon. TEA (0.83 mL 5.93 mmol, 1.1
equiv.) was added followed by sodium triacetoxyborohydride (0.97 g, 7.55 mmol, 1.4
equiv.). The mixture was stirred overnight then washed with saturated NaHC03 (3 x 50
mL). The organic layer was dried over Na2S 0 4 and evaporated. The residue was taken
up in hexanesrethyl acetate (4:1) and purified by flash column chromatography to yield
4.5, a yellow oil (2.56 g, 90%). lH NMR (250 MHz, CDC13) 5 0.92 (d, 6 H), 1.47 (s,
9H), 1.49 (s, 18H), 2.10 (m, 7H), 2.45 (t, 1H), 2.80 (d, 1H), 4.60 (d, 2H), 4.62 (m, 1H),
5.27 (m, 2H), 5.90 (m, 1H). I3C NMR (62.5 MHz, CDC13) 8  18.92, 19.31, 27.21, 27.56,
28.13, 28.33, 31.84, 48.25, 58.29, 65.72, 68.08, 80.86, 83.11, 119.09, 132.03, 152.31,
170.71, 174.82. FAB-MS 529 (M+H)*. Anal, calcd for C27H48N20 8: C, 59.34; H, 9.16;
N, 5.13. Found: C, 59.34, H, 8.76; N, 5.05.
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4.3.5 ferT-butyl (2S)-2-JV-l-[(5-carboxy)-(4R)-bis(iV; N'-tert-
butyloxycarbonylamino) pentyl]-2-amino-3-methyl-butanoate (4.6)
Compound 4.5 (1.77 g, 3.35 mmol) was dissolved in dry DCM (30 mL) under
argon. Morpholine (2.92 mL, 33.5 mmol, 10 equiv.) was added followed by Pd(PPh3)4
(0.42 g, 0.335 mmol, 0.1 equiv.). The solution was stirred for 30 minutes and then was
washed with IN HC1 (2 x 50 mL). A precipitate formed which was kept with the
organic layer. The organic layer is dried over Na2S04 and evaporated to yield a yellow
residue. The residue is taken up in CHCl3:MeOH (9:1) and purified by flash column
chromatography to yield 4.6, a yellow oil (1.39 g, 85%). 'H NMR (250 MHz, CDC13) 5
0.98 (m, 6 H), 1.47 (s, 9H), 1.48 (s, 18H), 1.62 (m, 1H), 2.18 (m, 6 H), 2.66 (m, 2H), 3.12
(d, 1H), 4.66 (m, 1H). ,3C NMR (62.5 MHz, CDC13) 5 18.27, 19.56, 26.37, 28.22,
28.34, 28.49, 30.93, 47.74, 50.92, 59.28, 66.96, 82.24, 82.76, 152.76, 172.08, 176.34.
FAB-MS 489 (M+H)+.
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4.3.6 3-(RHV',AT-[l,l-dunethylethoxy)carboiiyl]-am ino~l>[l>(S)- 
m ethylelhylethanoic acid]-2-piperidinone (4.7)
Compound 4.6 (1.05 g, 2.15 mmol) was dissolved in dry CH3CN (15 mL) and 
kept under argon. HATU (0.82 g, 2.15 mmol, 1 equiv.) was added, followed by DIEA 
(0.79 mL, 4.52 mmol, 2.1 equiv.). The solution was stirred for 2 hours after which the 
solvent was removed under reduced pressure. The residue was taken up in hexanes:ethyl 
acetate (3:1) and purified by flash column chromatography to give 4.7 as a white solid 
(0.78 g, 77%). ‘H NMR (250 MHz, CDC13) 8  0.98 (m, 6 H), 1.44 (s, 9H), 1.49 (s, I8H), 
1.69 (m, 1H), 1.84 (m, 2H), 2.15 (m, 2H), 3.28 (m, 1H), 3.56 (m, 1H), 4.78 (m, 1H), 
4.92 (d, 1H). 13C NMR (62.5 MHz, CDC13) 8  19.49, 19.96, 22.84, 27.10, 27.94, 28.31, 
43.85, 57.06, 61.99, 81.42, 82.71, 152.97, 168.45, 170.73. FAB-MS 472 (M+H)+. 
Anal, calcd for C24H42N20 7: C, 61.24; H, 9.00; N, 5.95. Found: C, 61.03; H, 8.65; N, 
6 .02 .
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4.3.7 3-(R)-jV '-[(9H-fluoren-9-ylmethoxy)carbonyl]-ainino-l-[l-(S)-
methylethylethanoic acid]-2-piperidinone
Compound 4.7 (1.32 g, 2.80 mmol) was treated with TFA/DCM (1:1,5 mL) and 
stirred for 15 minutes. The solvent was evaporated and the resulting yellow oil was taken 
up in sufficient 9% Na2C 0 3 to give a solution with pH 9. The solution was cooled in an 
ice bath and a solution of Fmoc-OSu (0.99 g, 2.94 mmol. 1.05 equiv.) in dioxane (10 
mL) was added. The solution was allowed to stir at room temperature for 2 hours after 
which the reaction mixture was diluted with water (100 mL). The reaction mixture was 
extracted with ether (1 x 50 mL) then with ethyl acetate (2 x 50 mL). The aqueous phase 
was cooled to 0° C, acidified to pH 2 with concentrated hydrochloric acid and then 
extracted with ethyl acetate (4 x 50 mL). The organic layer was dried over Na2S 0 4 and 
evaporated. The remaining clear oil is taken up in 1% acetic acid in CHCls/MeOH (9:1) 
and purified by flash column chromatography. The solvent was evaporated to yield 4.8 
as an off white solid (0.62 g, 51%). lH NMR (250 MHz, CDC13) 50.96 (d, 3H), 1.09 (d, 
3H), 1.28 (m, 1H), 2.07 (m, 2H), 2.45 (m, 2H), 3.47 (m, 2H), 4.26 (m, 3H), 4.41 (d, 
1H), 5.86 (m, 1H), 7.52 (m, 8 H). ,3C NMR (62.5 MHz, CDC13) 5 19.17, 19.99, 20.49, 
26.61, 27.15, 45.08, 47.09, 51.79, 64.78, 67.08, 119.89, 125.16, 127.05, 127.65, 141.26, 
143.81, 143.91, 156.34, 171.38, 173.43. FAB-MS 437 (M+H)+.
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Pmocr* O H
4.7 4.8
Alternative procedure for 4.8. Compound 4.7 (1.72 g, 3.65 mmol) was treated 
with TFA/DCM (1:1,5 mL) and stirred for 15 minutes. The solvent was evaporated and 
the resulting yellow oil was dissolved in dry DCM (30 mL). DIEA (1.97 mL, 11.3 
mmol, 3.1 equiv.) was added and the solution cooled to 0° C. TMS-C1 (0.92 mL, 7.28 
mmol, 2.0 equiv.) was added and the solution stirred for 2 hours. The solution was again 
cooled to 0° C and Fmoc-Cl (0.94 g, 3.64 mmol, 1.0 equiv.) dissolved in dry DCM (10 
mL) was added. The reaction was stirred for 4 hours at room temperature after which 
the DCM was evaporated. The residue was taken up in 2.5% Na2C 0 3 (25 mL) and 
washed with ether (2 x 50 mL). The aqueous layer was cooled to 0° C and acidified to 
pH 2 using concentrated hydrochloric acid. The precipitated product is extracted with 
ethyl acetate (4 x 50 mL). The organic layer is dried over Na2S 0 4 and the solvent 
removed to yield a clear oil. The crude product is taken up in 1% acetic acid in 
CHCl3/MeOH (9:1) and purified by flash column chromatography. The solvent was 
evaporated to yield 4.8 as an off white solid (1.37 g, 85%).
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4.3.8 Peptide Synthesis
The peptide under study was synthesized via solid-phase peptide synthesis using
a Milligen 9050 peptide synthesizer on PAL-PEG-PS solid support. Four equivalents of
each amino acid, 3 equivalents of DIEA, 4 equivalents of HATU and a one-hour
recycling time were used for the couplings. A solution of 20% piperidine/2% 1,8-
diazobicyclo[4.5.0]undec-7-ene (DBU) in DMF was used for Fmoc removal. The
peptide was acetylated on the solid support by treatment with a 0.2M solution of acetic
anhydride in 0.28M DIEA in DMF for 40 minutes. The peptide was simultaneously
cleaved from the resin and side-chain deprotected using reagent B, TFA,
4 30triisopropylsilane, water, phenol (8.8:0.2:0.5:0.5). The resulting acidic solution was
diluted with 30% acetic acid, washed with ether (4 x 50 mL) and lyophilized. The crude 
peptide was purified by preparative reverse-phase HPLC on a Waters 15 pM Deltapak 
C4 column using a water (0.05% TFA) and acetonitrile (0.05% TFA) gradient system. 
The gradient was run from 10% to 70% organic and the absorption monitored at 222 nm. 
Purity of the peptide was checked on a Vydac 5 pM Q 8 column using the same 
conditions. Matrix assisted laser desorption ionization (MALDI) mass spectrometry was 
used to verify peptide mass, 1093 (M+H)+.
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C hapter 5 
Sum m ary and Future Studies
5.1 Sum m ary and F u tu re  Studies
This dissertation focused on the synthesis and studies of helical peptides and the
synthesis of an amino acid designed to nucleate P-sheet dimer formation. The short,
helical peptides were rich in a , a-disubstituted amino acids (aaA A ’s) and designed to
be amphipathic. Helix preferences of the peptides in several solvent systems were
studied as was antimicrobial activity. A peptide utilizing the constrained lactam
dipeptide amino acid was synthesized and studied for p-sheet dimer formation.
Chapter 2 outlined the synthesis of short, amphipathic helical peptides. The helix
type and percent helicity of the peptides was determined using circular dichroism
spectroscopy. In addition, in vivo and in vitro studies were done to determine the
effectiveness of the peptides in eliminating intracellular pathogens. The peptides were
synthesized to determine if short, amphipathic peptides would exhibit increased
biological activity against bacteria versus mammalian cells. It has been shown that
5 1-5 4shorter peptides are more selective and more helical peptides are more active.
To increase the helicity of the peptides, aaA A ’s were used.5 '5 5-7 Pre-formed acid
fluorides of a-aminoisobutyric acid (Aib), 1-aminocyclohexanecarboxylic acid (Cyh)
5 8-5 9and 4-aminopiperidine-4-carboxylic acid (Api) were used in the synthesis. ' The
use of Api allowed a polar aaA A  to be used on the polar face of the amphipathic 
peptides. Once synthesized, the peptides were tested in vitro for direct antimicrobial 
activity against E. coli and S. aureus. All of the peptides showed good activity against E.
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coli while the more hydrophobic peptides, Cyh-10 and Ich-10 had excellent activity 
against S. aureus. Several of the peptides were tested against macrophages infected with 
intracellular pathogens. In vivo and in vitro studies were done to evaluate the 
effectiveness of several peptides in eliminating these pathogens. B. abortus and M. 
chelonei were used as representative intracellular pathogens. P i-10 and Ich-10 
significantly reduced the B. abortus load in BALB/c mice. Pi-10 showed a 90% B. 
abortus reduction with a single dose of 500 pg whereas Ich-10 showed an 82% B. 
abortus reduction with a single dose of 25 pg.
Brucella abortus expressing a green fluorescent protein and Mycobacterium 
chelonei were used to test if Pi-10 is selective in destroying only infected macrophages. 
Using these bacteria, infected macrophages can be visualized easily. Trypan blue 
exclusion identifies dead macrophages. Test results were promising. Further studies 
need to be done to improve control over the number of macrophages infected. In 
addition, fluorescently labeled peptides should be synthesized to determine the binding 
affinity of the peptides for infected versus non-infected macrophages.
Chapter 3 outlines the solvent effects on the helix preferences of a series of 
amphipathic peptides. P i-10 and Cyh-10 were designed to be amphipathic a-helical 
peptides while Ipi-10 and Ich-10 were designed to be amphipathic 310-helical peptides. 
All peptides contained 80% aaA A ’s.
According to the literature, P i-10 and Cyh-10 should display CD spectra typical 
for a 3 ,0-helix in SDS micelles due to their high aaA A  content and the position of the
proteinogenic amino acids.5'5’ 5 1 0  Instead, both peptides formed an a-helix in SDS
micelles, demonstrating the importance of amphipathy in determining helix preference.
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Ipi-10, a sequence permutation isomer of P i-10, showed the expected 3t0-helix spectrum. 
Ich-10, a sequence permutation isomer of Cyh-10, did not display a 3I0-helix spectrum as 
anticipated. Instead, a spectrum indicative of an a-helix was observed. It is theorized 
that the side-chains of the cyclohexyl amino acid residues are sterically congested in a 
3 ,0-helix, forcing the peptide to adopt an a-helix conformation.
Various organic and aqueous/organic solvent systems were studied to determine 
the effects on helix preferences. Pi-10 and Cyh-10 displayed a-helix spectra in all 
solvent systems. As expected, Ipi-10 adopted a 3,0-helix structure in 100% organic 
solvent but shifted to an a-helix as the water content increases. As in SDS micelles, Ich- 
10 adopted an a-helix conformation in all solvent systems tested. The demonstration 
that amphipathy, rather than aaA A  content, controls helix preference can be further 
investigated by altering the sequence of Ich-10 to reduce the steric hinderance of the 
side-chains.
Chapter 4 described the synthesis of 3-(R)-N -[(9H-fluoren-9- 
yImethoxy)carbonyl]-amino-1 -[ 1 -(S)-methylethylethanoic acid]-2-piperidinone, a
constrained lactam dipeptide amino acid. The amino acid was synthesized to incorporate 
into peptides designed to form intermolecular p-sheet dimers. The amino acid was 
synthesized beginning with the complete allyl esterification and double nitrogen 
protection of D-glutamic acid. The key step in the sequence is the selective DEBAL
reduction of the side-chain allyl ester to the aldehyde.5 ' 11 A reductive amination with L-
valine-OtBu is carried out followed by removal of the remaining allyl ester. Cyclization 
of the amino acid followed by removal of the a-nitrogen protecting groups and ferf-butyl
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ester on the valine moiety yielded the free constrained lactam dipeptide amino acid. 
Protection of the a-nitrogen with the Fmoc group gives the target amino acid ready for 
peptide synthesis.
The target amino acid was incorporated into a peptide pre-designed to form a 13-
sheet dimer. The structure of the peptide was studied in various solvents, pH levels and
concentrations. Unfortunately, only random coil spectra were observed. It is possible
that the minimum number of constrained lactam dipeptide amino acids has not been
reached. Future studies should concentrate on synthesizing a series of peptides, each
with increasing numbers of constrained lactam dipeptide amino acid residues. These
peptides can then be studied to determine the minimum number of constrained lactam
dipeptide amino acid residues needed to nucleate p-sheet dimer formation. It would also
prove helpful to synthesize a peptide containing a (3-tum. D-proline-glycine is a known 
5 12 5 13P-tum. ’ ’ Using this P-tum would result in an intramolecular P-sheet dimer,
rather than intermolecular, but it would aid greatly in the characterization of a p-sheet 
dimer.
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